Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SLDC Signs Letter of Intent, Starts Process of Acquisition of Fixed Wireless Access Provider
Solidus Communications, Inc.
Tue, May 2, 2023 at 3:21 PM GMT+2·3 min read
SLDC : 0.0043
52 Week Range 0.0021 - 0.0450
145.187.881 shares
= marketcap: $624.000
Total assets 1,094,437
Solidus announces start of due diligence of the acquisition of a major rural Florida fixed wireless access provider
ORMOND BEACH, FL, May 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Solidus Communications, Inc. (“Solidus” or the “Company”) (OTCPK: SLDC) signs Letter of Intent, starts process of Acquisition of Fixed Wireless Access Provider.
Dear Shareholders,
Solidus Communications’ trading/ticker symbol has transitioned to “SLDC”. Please ensure that your feeds and saved searches are updated to continue receiving our updates.
Solidus is pleased to announce that a Letter of Intent has been drafted, signed by Solidus and countersigned by the owners of a regional wireless internet service provider in Central Florida.
The acquisition, once completed, will add an additional 1 million dollars of revenue per year, approximately 1 million dollars in assets, and includes over 1 thousand customers who provide a residual monthly revenue of approximately 93,000 dollars per month.
Among the assets included in the sale are several corporate owned tower locations which will expand our reach in the area, connecting several disparate networks – expanding existing coverage areas.
Solidus is currently performing due diligence on the assets, financials, and customer accounts of the fixed wireless provider.
“The Fixed Wireless Access (FWA) segment is primed for an explosion. The available technology has improved, affording fiber-like speeds in the unlikeliest places. Technologies, such as Tarana’s CBRS 3Ghz units provide Solidus Communications with inroads into rural Florida and beyond. The application of the equipment to Rural America’s connectivity problems bridges the digital divide that currently marginalizes Rural America,” stated CEO William Sanchez.
Other acquisitions are being contemplated and will be made public as they coalesce.
“On our path to up list, quality acquisition targets, like this Fixed Wireless Access provider, will improve shareholder value, ensuring market acceptance of our business model. We are in good company, as evidenced by the number of large carriers making fixed wireless access an important component of their business model,” stated CEO William Sanchez.
Let the stronger hands prevail.
Thank You,
William J Sanchez
President & CEO
Solidus Communications, Inc.
william@soliduscommunications.com
(305) 747 – 7647
NON-SOLICITATION:
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.
FORWARD-LOOKING STATEMENTS:
This press release may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," "anticipate," "estimate," "expect," "intend," and "project" and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guarantees of future results and conditions but rather are subject to various risks and uncertainties. Some of these risks and uncertainties are identified in the company's filings with the SEC. The occurrence of any of these risks and uncertainties could have a material adverse effect on the company's business, financial condition, and results of operations.
Contact us at:
William J Sanchez
Chairman/CEO
william@soliduscommunications.com
(305) 747 7647 x 101
Follow "SLDC" on Twitter: @soldiusSLDC
Stock Symbol: SLCD
Company Website: www.soliduscommunications.com
Opgen (OPGN) after hours: 1.34 + 0.51 (61.45%)
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
ROCKVILLE, Md., April 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has met the remaining key milestones under the initial research and development (“R&D”) collaboration agreement with FIND. Following the delivery of a comprehensive milestone report at the end of first quarter of 2023, FIND confirmed that all requirements have been met successfully. Under the recently announced expansion of the collaboration, the originally planned Next Generation Sequencing (“NGS”) strain analysis will be complemented with isolates from other sub-Saharan African countries. Completion of the deliverables triggered a milestone payment of approximately $0.3 million.
The R&D collaboration to date has successfully addressed the development and initial wet-lab testing of a sample-in to result-out Unyvero A30 panel with 33 targets, including fully integrated sample preparation. Multiple Unyvero A30 instrument adaptations were made to optimize for use in the challenging environments of low- and middle- income countries (LMICs). Instrument prototypes have been designed, built and tested for operation in high-dust, extended temperature range and power-out scenarios.
Andreas Boos, Chief Technology Officer at Curetis GmbH commented: “We are excited to have successfully delivered the final milestones from the first phase of our collaboration agreement and look forward to working on the next set of deliverables under the expanded scope of our R&D partnership with FIND.”
Johannes Bacher, Chief Operating Officer of OpGen added: “We believe the successful first phase of our development collaboration puts us in an ideal position towards development of a robust solution optimized for use in LMICs, a goal we would like to pursue during a potential next phase of this collaboration under a new agreement with FIND.”
Dr. Cecilia Ferreyra, Director, FIND AMR Programme remarked that, “We have evaluated the final milestone data from Curetis on the Unyvero A30 and have confirmed that the adapted prototype test meets the quality and accuracy requirements for use in low- and middle-income countries. We look forward to potential continued collaboration to expand testing for blood stream infections in LMIC hospitals so that people can be linked to the care they need as soon as possible.”
About OpGen, Inc.
OpGen, Inc. (Rockville, Md., U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
Opgen (OPGN) after hours: 1.34 + 0.51 (61.45%)
OpGen’s Subsidiary Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
ROCKVILLE, Md., April 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported today that its German subsidiary Curetis GmbH has met the remaining key milestones under the initial research and development (“R&D”) collaboration agreement with FIND. Following the delivery of a comprehensive milestone report at the end of first quarter of 2023, FIND confirmed that all requirements have been met successfully. Under the recently announced expansion of the collaboration, the originally planned Next Generation Sequencing (“NGS”) strain analysis will be complemented with isolates from other sub-Saharan African countries. Completion of the deliverables triggered a milestone payment of approximately $0.3 million.
The R&D collaboration to date has successfully addressed the development and initial wet-lab testing of a sample-in to result-out Unyvero A30 panel with 33 targets, including fully integrated sample preparation. Multiple Unyvero A30 instrument adaptations were made to optimize for use in the challenging environments of low- and middle- income countries (LMICs). Instrument prototypes have been designed, built and tested for operation in high-dust, extended temperature range and power-out scenarios.
Andreas Boos, Chief Technology Officer at Curetis GmbH commented: “We are excited to have successfully delivered the final milestones from the first phase of our collaboration agreement and look forward to working on the next set of deliverables under the expanded scope of our R&D partnership with FIND.”
Johannes Bacher, Chief Operating Officer of OpGen added: “We believe the successful first phase of our development collaboration puts us in an ideal position towards development of a robust solution optimized for use in LMICs, a goal we would like to pursue during a potential next phase of this collaboration under a new agreement with FIND.”
Dr. Cecilia Ferreyra, Director, FIND AMR Programme remarked that, “We have evaluated the final milestone data from Curetis on the Unyvero A30 and have confirmed that the adapted prototype test meets the quality and accuracy requirements for use in low- and middle-income countries. We look forward to potential continued collaboration to expand testing for blood stream infections in LMIC hospitals so that people can be linked to the care they need as soon as possible.”
About OpGen, Inc.
OpGen, Inc. (Rockville, Md., U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc
Tue, April 25, 2023 at 10:05 PM GMT+2·16 min read
In this article:
Continued Sequential Quarterly Growth in the U.S. With Q4 Revenues of $2.7 Million
Improved Operational Effectiveness With Second Half 2022 Operating Expenses Down 27.9% Compared to the First Half of 2022, A $5.1 Million Reduction
Executing A Plan For Profitability With A Balance Sheet Bolstered By Approximately $16.0 Million Raised Over the Last 12 Months
Conference Call to be Held at 4:30 pm ET Today
SAN CLEMENTE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the year ended December 31, 2022 and provided a corporate strategic update.
Fourth Quarter 2022 and Subsequent Highlights
In April, completed a $2.5 million registered direct offering with a single institutional investor, extending the company's cash runway into 2024, creating a sustainable path to profitability.
In April, received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to the company’s Obalon® Balloon System, expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
In March, formed a Scientific Advisory Board (SAB) comprised of internationally recognized experts and surgeons in the obesity and metabolic disease fields. The newly created SAB will provide management with strategic input and external scientific review of the company’s development activities and product pipeline.
In February, raised $10.2 million in an upsized underwritten public offering.
In December, obtained shareholder approval for, and effected, a 1-for-50 reverse stock split in order to regain compliance with the Nasdaq minimum bid price requirement.
In November, completed a $750,000 registered direct offering with a single institutional shareholder.
In October, presented data at the Obesity Society Annual Meeting, during ObesityWeek®, on ReShape’s DBSN™ device as a potential treatment for Type 2 diabetes, in an abstract entitled, Metabolic Effects of Dual Neuromodulation of Vagus Nerve in a Type 2 Diabetic Model.
In October, announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) issued updated guidelines for Metabolic and Bariatric Surgery, including the Lap-Band®, replacing the 30 year old guidelines issued by the National Institutes of Health (NIH) in 1991.
In October, announced publication of data on the company’s proprietary DBSN™ system for the treatment of Type 2 diabetes and metabolic disorders in the Neural Technology Section of the peer reviewed journal, Frontiers in NeuroScience.
In October, announced that the ASMBS issued a Consensus Statement on Lap-Band® use and aftercare management, entitled, American Society of Metabolic and Bariatric Surgery Consensus Statement on Laparoscopic Adjustable Gastric Band Management.
“Since the latter half of 2022, we have continued to execute on our growth pillars with a metrics driven approach to business operations, while expanding our evidenced-based product portfolio spanning the entire care continuum to treat obesity and metabolic disease. Our upsized $10.2 million underwritten public offering, completed in February, along with the recent $2.5 million registered direct offering in April, gives us sufficient cash to achieve profitability within the next 18 months and provides an additional layer of capital to help drive growth,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences®. “We intend to work closely with our recently formed global SAB, whose members will be providing their expertise and feedback on our growth initiatives and will be integral in helping us develop safe and effective products and programs for durable weight loss, improvements in obesity related comorbidities and quality of life. Additionally, the compelling evidence-based standards for metabolic and bariatric surgery issued by the industry’s two key organizations, ASMBS and IFSO, if supported by payers, can dramatically increase the number of patients eligible for bariatric surgery. Our strong belief is that our Lap-Band® System will prevail as the least invasive surgical treatment option available to help address the global obesity epidemic. Going forward, we remain committed to continuing our collaborations with healthcare professionals to expand awareness and use of personalized treatments, including both our proprietary Lap-Band® and ReShapeCare™ programs, to ensure that patients can achieve durable long-term weight loss goals.
“Operationally, we made a number of changes to ensure more predictable and scalable future financial performance including right-sizing the organization to reduce operating expenditures and allow more investment in our growth drivers, including sales and marketing. Shortly after I joined ReShape in August, we implemented a highly targeted, direct-to-consumer marketing campaign to help yield higher quality and lower cost patient leads for the anatomy sparing Lap-Band® in specific markets that align with surgeon advocates. We are continuing to upgrade our lead generating and nurturing programs and will be moving critical competencies in-house to ensure results are achieved quickly and cost-effectively.”
Management noted that its focus on introducing new products and services, the second of its growth pillars, includes:
The recent launch of the re-designed ReShape Calibration Tubes, which support the majority of all bariatric procedures. Initial surgeon feedback is positive, and the company expects to achieve revenue from new customer adoption of the Calibration Tubes during 2023.
The expected submission, in the second quarter, of a PMA Supplement to the U.S. Food and Drug Administration (FDA) for approval of the Lap-Band® 2.0 System, designed to reduce the required postoperative physician office-based Lap-Band adjustments. Feedback from the FDA is expected by year end 2023.
Continuing to work with large, self-insured employers to provide the HIPAA-compliant, novel, weight management program, ReShapeCare™, to their employees in order to positively impact overall employee health and thus reduce employers’ health care costs.
Continued the development of the proprietary DBSN™ technology though non-dilutive NIH SBIR grant support. The DBSN™ incorporates a vagus nerve block technology platform with vagus nerve stimulation, which may be able to reduce diabetes patients’ dependence on medications in a very individualized manner. The device has the potential to address the significant type 2 diabetes market.
Mr. Hickey concluded, “As evidenced by the recent Notice of Allowance from the USPTO for an additional patent covering the ReShape Obalon® Balloon system, we have a strong defensive ‘moat’ of intellectual property surrounding all of our products, including the Lap-Band®, Lap-Band® 2.0, DBSN™ technology, and the ReShape Obalon® Balloon system. Looking ahead, we are at the precipice of some exciting milestones and compelling new product launches, and remain laser focused on executing on our growth pillars, which have put us on a path to profitability.”
Year Ended December 31, 2022, Financial and Operating Results
The information shown below will focus primarily on our full year 2022 financial results. Additionally, we will also highlight the great strides we made during the second half of 2022, as we focused our business strategy and significantly reduced costs, which will serve as both our launch pad for growth and path to profitability.
During the second half of 2022, we pivoted our marketing strategy which has significantly reduced our sales and marketing expenses quarter over quarter. We also reduced our G&A and R&D expenses in order to operate more efficiently and reduce our cash burn. To give you more perspective, and before any significant one-time adjustments, our overall operating expenses in the first half of 2022 were $18.1 million compared to $13.0 million for the second half of 2022 a reduction of $5.1 million, or 27.9%. This is a significant reduction in our cash burn, which will pave the way for ReShape to become profitable, sooner.
Revenue totaled $11.2 million for the year ended December 31, 2022, which represents a contraction of 17.4%, or $2.4 million compared to 2021. The decline was primarily attributable to the re-emergence of COVID. Nevertheless, we saw sequential growth in each quarter during 2022 in our U.S. business. Our U.S revenue for the first half of 2022 was $4.2 million vs $5.1 million for the second half of 2022, an increase of $0.9 million, or 22.3%.
Gross Profit for the year ended December 31, 2022, was $6.8 million, compared to $8.3 million for the year ended December 31, 2021, a decrease of $1.5 million or 18.1%. Gross profit as a percentage of revenue for the year ended December 31, 2022, was 60.5% compared to 61.4% for 2021. The decrease in gross profit margin is primarily due to a decrease in sales, as revenue decreased by 17.4%, with the largest decrease of revenue in the U.S., which has a higher margin than international sales. During the first half of 2022, our gross margins were 58.2% compared to 62.6% for the second half of 2022 as our U.S revenues began to increase.
Sales and Marketing Expenses for the year ended December 31, 2022, rose by $5.2 million, or 58.5%, to $14.1 million, compared to $8.9 million for 2021. The increase was primarily due to an increase in advertising and marketing costs, as well as payroll related and travel expenses, and expenses related to the development of the ReShapeCare™ platform, all totaling an increase of $6.1 million. This increase was offset by a decline in stock-based compensation expense, commissions and other related costs of $0.9 million. During the first half of 2022, our sales and marketing expenses were $9.4 million compared to $4.8 million in the second half of 2022, a decline of $4.6 million, or 48.9%.
General and Administrative Expenses for the year ended December 31, 2022, decreased by $7.1 million, or 28.5%, to $17.4 million, compared to $24.3 million for 2021. The decrease is primarily due to a decline in stock-based compensation expense, and a reduction in consulting and professional fees totaling $10.4 million. This decrease was primarily offset by accrued litigation expenses and severance costs totaling $3.3 million. During the first half of 2022 our general and administrative expenses were $9.6 million compared to $7.7 million in the second half of 2022, a decrease of $1.9 million, or 19.4%.
Research and Development Expenses for the year ended December 31, 2022, increased by $0.2 million, or 7.3% to $2.5 million, compared to $2.3 million for 2021. The increase is primarily due to an increase in consulting and professional services related to the development of ReShape’s Diabetes Bloc-Stim Neuromodulation™ device and payroll related expenditures. Our R&D expenses for the first half of 2022 were $1.5 million compared to $1.0 million for the second half of 2022, a decrease of $0.5 million, or 30.0%.
Cash and Cash Equivalents as of December 31, 2022 were $3.9 million and the company remains debt free on its balance sheet. Additionally, in February and April 2023, we completed two financings totaling $12.6 million. Based on available cash resources, the company believes there is sufficient cash on hand to fund current operations into 2024.
A full discussion of our financials is available in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission.
ReShape Lifesciences® Reports Year Ended December 31, 2022 Financial Results and Provides Corporate Update
ReShape Lifesciences Inc
Tue, April 25, 2023 at 10:05 PM GMT+2·16 min read
In this article:
Continued Sequential Quarterly Growth in the U.S. With Q4 Revenues of $2.7 Million
Improved Operational Effectiveness With Second Half 2022 Operating Expenses Down 27.9% Compared to the First Half of 2022, A $5.1 Million Reduction
Executing A Plan For Profitability With A Balance Sheet Bolstered By Approximately $16.0 Million Raised Over the Last 12 Months
Conference Call to be Held at 4:30 pm ET Today
SAN CLEMENTE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the year ended December 31, 2022 and provided a corporate strategic update.
Fourth Quarter 2022 and Subsequent Highlights
In April, completed a $2.5 million registered direct offering with a single institutional investor, extending the company's cash runway into 2024, creating a sustainable path to profitability.
In April, received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to the company’s Obalon® Balloon System, expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
In March, formed a Scientific Advisory Board (SAB) comprised of internationally recognized experts and surgeons in the obesity and metabolic disease fields. The newly created SAB will provide management with strategic input and external scientific review of the company’s development activities and product pipeline.
In February, raised $10.2 million in an upsized underwritten public offering.
In December, obtained shareholder approval for, and effected, a 1-for-50 reverse stock split in order to regain compliance with the Nasdaq minimum bid price requirement.
In November, completed a $750,000 registered direct offering with a single institutional shareholder.
In October, presented data at the Obesity Society Annual Meeting, during ObesityWeek®, on ReShape’s DBSN™ device as a potential treatment for Type 2 diabetes, in an abstract entitled, Metabolic Effects of Dual Neuromodulation of Vagus Nerve in a Type 2 Diabetic Model.
In October, announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) issued updated guidelines for Metabolic and Bariatric Surgery, including the Lap-Band®, replacing the 30 year old guidelines issued by the National Institutes of Health (NIH) in 1991.
In October, announced publication of data on the company’s proprietary DBSN™ system for the treatment of Type 2 diabetes and metabolic disorders in the Neural Technology Section of the peer reviewed journal, Frontiers in NeuroScience.
In October, announced that the ASMBS issued a Consensus Statement on Lap-Band® use and aftercare management, entitled, American Society of Metabolic and Bariatric Surgery Consensus Statement on Laparoscopic Adjustable Gastric Band Management.
“Since the latter half of 2022, we have continued to execute on our growth pillars with a metrics driven approach to business operations, while expanding our evidenced-based product portfolio spanning the entire care continuum to treat obesity and metabolic disease. Our upsized $10.2 million underwritten public offering, completed in February, along with the recent $2.5 million registered direct offering in April, gives us sufficient cash to achieve profitability within the next 18 months and provides an additional layer of capital to help drive growth,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences®. “We intend to work closely with our recently formed global SAB, whose members will be providing their expertise and feedback on our growth initiatives and will be integral in helping us develop safe and effective products and programs for durable weight loss, improvements in obesity related comorbidities and quality of life. Additionally, the compelling evidence-based standards for metabolic and bariatric surgery issued by the industry’s two key organizations, ASMBS and IFSO, if supported by payers, can dramatically increase the number of patients eligible for bariatric surgery. Our strong belief is that our Lap-Band® System will prevail as the least invasive surgical treatment option available to help address the global obesity epidemic. Going forward, we remain committed to continuing our collaborations with healthcare professionals to expand awareness and use of personalized treatments, including both our proprietary Lap-Band® and ReShapeCare™ programs, to ensure that patients can achieve durable long-term weight loss goals.
“Operationally, we made a number of changes to ensure more predictable and scalable future financial performance including right-sizing the organization to reduce operating expenditures and allow more investment in our growth drivers, including sales and marketing. Shortly after I joined ReShape in August, we implemented a highly targeted, direct-to-consumer marketing campaign to help yield higher quality and lower cost patient leads for the anatomy sparing Lap-Band® in specific markets that align with surgeon advocates. We are continuing to upgrade our lead generating and nurturing programs and will be moving critical competencies in-house to ensure results are achieved quickly and cost-effectively.”
Management noted that its focus on introducing new products and services, the second of its growth pillars, includes:
The recent launch of the re-designed ReShape Calibration Tubes, which support the majority of all bariatric procedures. Initial surgeon feedback is positive, and the company expects to achieve revenue from new customer adoption of the Calibration Tubes during 2023.
The expected submission, in the second quarter, of a PMA Supplement to the U.S. Food and Drug Administration (FDA) for approval of the Lap-Band® 2.0 System, designed to reduce the required postoperative physician office-based Lap-Band adjustments. Feedback from the FDA is expected by year end 2023.
Continuing to work with large, self-insured employers to provide the HIPAA-compliant, novel, weight management program, ReShapeCare™, to their employees in order to positively impact overall employee health and thus reduce employers’ health care costs.
Continued the development of the proprietary DBSN™ technology though non-dilutive NIH SBIR grant support. The DBSN™ incorporates a vagus nerve block technology platform with vagus nerve stimulation, which may be able to reduce diabetes patients’ dependence on medications in a very individualized manner. The device has the potential to address the significant type 2 diabetes market.
Mr. Hickey concluded, “As evidenced by the recent Notice of Allowance from the USPTO for an additional patent covering the ReShape Obalon® Balloon system, we have a strong defensive ‘moat’ of intellectual property surrounding all of our products, including the Lap-Band®, Lap-Band® 2.0, DBSN™ technology, and the ReShape Obalon® Balloon system. Looking ahead, we are at the precipice of some exciting milestones and compelling new product launches, and remain laser focused on executing on our growth pillars, which have put us on a path to profitability.”
Year Ended December 31, 2022, Financial and Operating Results
The information shown below will focus primarily on our full year 2022 financial results. Additionally, we will also highlight the great strides we made during the second half of 2022, as we focused our business strategy and significantly reduced costs, which will serve as both our launch pad for growth and path to profitability.
During the second half of 2022, we pivoted our marketing strategy which has significantly reduced our sales and marketing expenses quarter over quarter. We also reduced our G&A and R&D expenses in order to operate more efficiently and reduce our cash burn. To give you more perspective, and before any significant one-time adjustments, our overall operating expenses in the first half of 2022 were $18.1 million compared to $13.0 million for the second half of 2022 a reduction of $5.1 million, or 27.9%. This is a significant reduction in our cash burn, which will pave the way for ReShape to become profitable, sooner.
Revenue totaled $11.2 million for the year ended December 31, 2022, which represents a contraction of 17.4%, or $2.4 million compared to 2021. The decline was primarily attributable to the re-emergence of COVID. Nevertheless, we saw sequential growth in each quarter during 2022 in our U.S. business. Our U.S revenue for the first half of 2022 was $4.2 million vs $5.1 million for the second half of 2022, an increase of $0.9 million, or 22.3%.
Gross Profit for the year ended December 31, 2022, was $6.8 million, compared to $8.3 million for the year ended December 31, 2021, a decrease of $1.5 million or 18.1%. Gross profit as a percentage of revenue for the year ended December 31, 2022, was 60.5% compared to 61.4% for 2021. The decrease in gross profit margin is primarily due to a decrease in sales, as revenue decreased by 17.4%, with the largest decrease of revenue in the U.S., which has a higher margin than international sales. During the first half of 2022, our gross margins were 58.2% compared to 62.6% for the second half of 2022 as our U.S revenues began to increase.
Sales and Marketing Expenses for the year ended December 31, 2022, rose by $5.2 million, or 58.5%, to $14.1 million, compared to $8.9 million for 2021. The increase was primarily due to an increase in advertising and marketing costs, as well as payroll related and travel expenses, and expenses related to the development of the ReShapeCare™ platform, all totaling an increase of $6.1 million. This increase was offset by a decline in stock-based compensation expense, commissions and other related costs of $0.9 million. During the first half of 2022, our sales and marketing expenses were $9.4 million compared to $4.8 million in the second half of 2022, a decline of $4.6 million, or 48.9%.
General and Administrative Expenses for the year ended December 31, 2022, decreased by $7.1 million, or 28.5%, to $17.4 million, compared to $24.3 million for 2021. The decrease is primarily due to a decline in stock-based compensation expense, and a reduction in consulting and professional fees totaling $10.4 million. This decrease was primarily offset by accrued litigation expenses and severance costs totaling $3.3 million. During the first half of 2022 our general and administrative expenses were $9.6 million compared to $7.7 million in the second half of 2022, a decrease of $1.9 million, or 19.4%.
Research and Development Expenses for the year ended December 31, 2022, increased by $0.2 million, or 7.3% to $2.5 million, compared to $2.3 million for 2021. The increase is primarily due to an increase in consulting and professional services related to the development of ReShape’s Diabetes Bloc-Stim Neuromodulation™ device and payroll related expenditures. Our R&D expenses for the first half of 2022 were $1.5 million compared to $1.0 million for the second half of 2022, a decrease of $0.5 million, or 30.0%.
Cash and Cash Equivalents as of December 31, 2022 were $3.9 million and the company remains debt free on its balance sheet. Additionally, in February and April 2023, we completed two financings totaling $12.6 million. Based on available cash resources, the company believes there is sufficient cash on hand to fund current operations into 2024.
A full discussion of our financials is available in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission.
ReShape Lifesciences Inc. (RSLS) : 2.57
52 Week Range 2.49 - 77.0000
Very low free float and only 483.529 shares.
MATTHEW NACHTRAB REPORTS 27.7% STAKE IN RESHAPE LIFESCIENCES AS
NACHTRAB-PURCHASED CO'S COMMON STOCK BASED ON BELIEF THAT SUCH SECURITIES, AT CURRENT MARKET PRICES, REPRESENTED AN ATTRACTIVE INVESTMENT OPPORTUNITY
NACHTRAB - WROTE A LETTER TO THE CEO OF CO WITH RECOMMENDATIONS FOR THE MANAGEMENT TEAM’S STRATEGY GOING FORWARD
https://ir.reshapelifesciences.com/static-files/aa8a67f3-70fe-4b27-aa86-95ba8c3ce91a
I am excited for your new tenure as CEO of ReShape Lifesciences and I believe your team can rebuild and create a $100m plus market cap company with some austerity measures, leveraging assets currently owned, and capitalizing on the medicated weight loss secular trend to generate lead flow and massive revenue growth. I am willing to discuss this and advise in any way I can help.
Time for a strong rebound:
Feb 03, 2023 13.1400 22.4000 11.5600 17.0400 17.0400 11,599,000
Jan 03, 2023 9.6600 20.6300 9.4500 15.6600 15.6600 12,363,900
ReShape Lifesciences Inc. (RSLS) : 2.57
52 Week Range 2.49 - 77.0000
Very low free float and only 483.529 shares.
MATTHEW NACHTRAB REPORTS 27.7% STAKE IN RESHAPE LIFESCIENCES AS
NACHTRAB-PURCHASED CO'S COMMON STOCK BASED ON BELIEF THAT SUCH SECURITIES, AT CURRENT MARKET PRICES, REPRESENTED AN ATTRACTIVE INVESTMENT OPPORTUNITY
NACHTRAB - WROTE A LETTER TO THE CEO OF CO WITH RECOMMENDATIONS FOR THE MANAGEMENT TEAM’S STRATEGY GOING FORWARD
https://ir.reshapelifesciences.com/static-files/aa8a67f3-70fe-4b27-aa86-95ba8c3ce91a
I am excited for your new tenure as CEO of ReShape Lifesciences and I believe your team can rebuild and create a $100m plus market cap company with some austerity measures, leveraging assets currently owned, and capitalizing on the medicated weight loss secular trend to generate lead flow and massive revenue growth. I am willing to discuss this and advise in any way I can help.
Time for a strong rebound:
Feb 03, 2023 13.1400 22.4000 11.5600 17.0400 17.0400 11,599,000
Jan 03, 2023 9.6600 20.6300 9.4500 15.6600 15.6600 12,363,900
Lannett (LCIN) : 0.1495 + 10.74%
52w: 0.12 – 3.72
mktcap: 1.5 million
https://www.findacode.com/ndc/labelers/Lannett_Company%2C_Inc.
Shares Outstanding 10.77M
Float 8.39M
Total Cash (mrq) 55.85M
Total Debt (mrq) 635.37M
Results of Insulin Study
The pivotal clinical trial of biosimilar insulin glargine demonstrated positive results, in line with prior expectations. The Company is co-developing this product with its strategic alliance partners within the HEC Group of companies (HEC). The single center, single-dose, double-blind, randomized, two-period, two-treatment, two-sequence, crossover study was designed to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) similarity between Lannett/HECs biosimilar insulin glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers. The study met all of its primary and secondary endpoints and no serious adverse events were reported. The data from the pivotal trial of the Company's biosimilar insulin glargine indicate that its insulin glargine is biosimilar to the reference product.
"We are pleased with the results of this crucial clinical trial of biosimilar insulin glargine," said Tim Crew, chief executive officer of Lannett. "We remain confident that biosimilar insulin glargine represents a significant commercial opportunity, and our team is diligently focused on advancing this product."
Lannett is moving forward expeditiously to complete the Biologics License Application, with the goal of submitting the application to the FDA within the next several months. Prior to filing, there are additional meaningful activities to complete, including a device differentiation study, which will run in April, and more comparability work showing HEC's insulin glargine is biosimilar to US sourced Lantus. Lannett also anticipates engaging with the FDA in a pre-submission meeting. There are significant steps necessary for the Company to receive FDA approval to effectively commercialize this product, and there is no guarantee that the Company will be successful in this regard.
The Company continues to assess the potential impacts of recent developments in the insulin market, including announcements by manufacturers related to lowering the price of insulin for patients, especially list prices, and enhancing market transparency. Lannett welcomes these initiatives to help drive greater access to this critical medicine and believes these changes dovetail with the Company's promising go-to-market approach.
Q2 Business and Financial Highlights:
• Net Sales were $80.9 Million
• Gross Margin was 18%, Adjusted Gross Margin was 19%
• Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
• $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st
Pipeline Updates:
• Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
• Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
• Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
• Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year
Apr 24, 2023 0.2300 0.2850 0.2094 0.2850 0.2850 40,646
Apr 21, 2023 0.3500 0.3500 0.2300 0.2300 0.2300 668,300
Apr 20, 2023 0.6600 0.7000 0.2500 0.3330 0.3330 1,167,800
Apr 19, 2023 0.6500 0.7196 0.6501 0.6855 0.6855 280,660
Apr 18, 2023 0.6530 0.6829 0.6530 0.6600 0.6600 30,585
Apr 17, 2023 0.7000 0.7000 0.6525 0.6525 0.6525 39,745
Apr 14, 2023 0.6400 0.7200 0.6375 0.6900 0.6900 129,657
Apr 13, 2023 0.6400 0.6960 0.6400 0.6700 0.6700 60,850
Apr 12, 2023 0.7600 0.7700 0.6600 0.6620 0.6620 126,490
Apr 11, 2023 0.9400 0.9478 0.7200 0.7221 0.7221 185,385
Apr 10, 2023 0.9750 0.9800 0.9067 0.9179 0.9179 30,979
Apr 06, 2023 0.9400 0.9500 0.9100 0.9205 0.9205 72,475
Apr 05, 2023 0.9800 0.9975 0.9300 0.9539 0.9539 312,304
Apr 04, 2023 1.8500 1.8500 0.8600 0.9700 0.9700 982,984
Apr 03, 2023 1.6800 1.8900 1.6800 1.8700 1.8700 25,574
Lannett (LCIN) : 0.1495 + 10.74%
52w: 0.12 – 3.72
mktcap: 1.5 million
https://www.findacode.com/ndc/labelers/Lannett_Company%2C_Inc.
Shares Outstanding 10.77M
Float 8.39M
Total Cash (mrq) 55.85M
Total Debt (mrq) 635.37M
Results of Insulin Study
The pivotal clinical trial of biosimilar insulin glargine demonstrated positive results, in line with prior expectations. The Company is co-developing this product with its strategic alliance partners within the HEC Group of companies (HEC). The single center, single-dose, double-blind, randomized, two-period, two-treatment, two-sequence, crossover study was designed to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) similarity between Lannett/HECs biosimilar insulin glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers. The study met all of its primary and secondary endpoints and no serious adverse events were reported. The data from the pivotal trial of the Company's biosimilar insulin glargine indicate that its insulin glargine is biosimilar to the reference product.
"We are pleased with the results of this crucial clinical trial of biosimilar insulin glargine," said Tim Crew, chief executive officer of Lannett. "We remain confident that biosimilar insulin glargine represents a significant commercial opportunity, and our team is diligently focused on advancing this product."
Lannett is moving forward expeditiously to complete the Biologics License Application, with the goal of submitting the application to the FDA within the next several months. Prior to filing, there are additional meaningful activities to complete, including a device differentiation study, which will run in April, and more comparability work showing HEC's insulin glargine is biosimilar to US sourced Lantus. Lannett also anticipates engaging with the FDA in a pre-submission meeting. There are significant steps necessary for the Company to receive FDA approval to effectively commercialize this product, and there is no guarantee that the Company will be successful in this regard.
The Company continues to assess the potential impacts of recent developments in the insulin market, including announcements by manufacturers related to lowering the price of insulin for patients, especially list prices, and enhancing market transparency. Lannett welcomes these initiatives to help drive greater access to this critical medicine and believes these changes dovetail with the Company's promising go-to-market approach.
Q2 Business and Financial Highlights:
• Net Sales were $80.9 Million
• Gross Margin was 18%, Adjusted Gross Margin was 19%
• Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
• $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st
Pipeline Updates:
• Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
• Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
• Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
• Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year
Apr 24, 2023 0.2300 0.2850 0.2094 0.2850 0.2850 40,646
Apr 21, 2023 0.3500 0.3500 0.2300 0.2300 0.2300 668,300
Apr 20, 2023 0.6600 0.7000 0.2500 0.3330 0.3330 1,167,800
Apr 19, 2023 0.6500 0.7196 0.6501 0.6855 0.6855 280,660
Apr 18, 2023 0.6530 0.6829 0.6530 0.6600 0.6600 30,585
Apr 17, 2023 0.7000 0.7000 0.6525 0.6525 0.6525 39,745
Apr 14, 2023 0.6400 0.7200 0.6375 0.6900 0.6900 129,657
Apr 13, 2023 0.6400 0.6960 0.6400 0.6700 0.6700 60,850
Apr 12, 2023 0.7600 0.7700 0.6600 0.6620 0.6620 126,490
Apr 11, 2023 0.9400 0.9478 0.7200 0.7221 0.7221 185,385
Apr 10, 2023 0.9750 0.9800 0.9067 0.9179 0.9179 30,979
Apr 06, 2023 0.9400 0.9500 0.9100 0.9205 0.9205 72,475
Apr 05, 2023 0.9800 0.9975 0.9300 0.9539 0.9539 312,304
Apr 04, 2023 1.8500 1.8500 0.8600 0.9700 0.9700 982,984
Apr 03, 2023 1.6800 1.8900 1.6800 1.8700 1.8700 25,574
Lannett (LCIN) : 0.149 - 35.22%
today: 149 - 0.285
52w: 0.149 – 3.72
mktcap: 1.6 million
https://www.findacode.com/ndc/labelers/Lannett_Company%2C_Inc.
Shares Outstanding 10.77M
Float 8.39M
Total Cash (mrq) 55.85M
Total Debt (mrq) 635.37M
Results of Insulin Study
The pivotal clinical trial of biosimilar insulin glargine demonstrated positive results, in line with prior expectations. The Company is co-developing this product with its strategic alliance partners within the HEC Group of companies (HEC). The single center, single-dose, double-blind, randomized, two-period, two-treatment, two-sequence, crossover study was designed to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) similarity between Lannett/HECs biosimilar insulin glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers. The study met all of its primary and secondary endpoints and no serious adverse events were reported. The data from the pivotal trial of the Company's biosimilar insulin glargine indicate that its insulin glargine is biosimilar to the reference product.
"We are pleased with the results of this crucial clinical trial of biosimilar insulin glargine," said Tim Crew, chief executive officer of Lannett. "We remain confident that biosimilar insulin glargine represents a significant commercial opportunity, and our team is diligently focused on advancing this product."
Lannett is moving forward expeditiously to complete the Biologics License Application, with the goal of submitting the application to the FDA within the next several months. Prior to filing, there are additional meaningful activities to complete, including a device differentiation study, which will run in April, and more comparability work showing HEC's insulin glargine is biosimilar to US sourced Lantus. Lannett also anticipates engaging with the FDA in a pre-submission meeting. There are significant steps necessary for the Company to receive FDA approval to effectively commercialize this product, and there is no guarantee that the Company will be successful in this regard.
The Company continues to assess the potential impacts of recent developments in the insulin market, including announcements by manufacturers related to lowering the price of insulin for patients, especially list prices, and enhancing market transparency. Lannett welcomes these initiatives to help drive greater access to this critical medicine and believes these changes dovetail with the Company's promising go-to-market approach.
Q2 Business and Financial Highlights:
• Net Sales were $80.9 Million
• Gross Margin was 18%, Adjusted Gross Margin was 19%
• Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
• $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st
Pipeline Updates:
• Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
• Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
• Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
• Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year
Apr 24, 2023 0.2300 0.2850 0.2094 0.2850 0.2850 40,646
Apr 21, 2023 0.3500 0.3500 0.2300 0.2300 0.2300 668,300
Apr 20, 2023 0.6600 0.7000 0.2500 0.3330 0.3330 1,167,800
Apr 19, 2023 0.6500 0.7196 0.6501 0.6855 0.6855 280,660
Apr 18, 2023 0.6530 0.6829 0.6530 0.6600 0.6600 30,585
Apr 17, 2023 0.7000 0.7000 0.6525 0.6525 0.6525 39,745
Apr 14, 2023 0.6400 0.7200 0.6375 0.6900 0.6900 129,657
Apr 13, 2023 0.6400 0.6960 0.6400 0.6700 0.6700 60,850
Apr 12, 2023 0.7600 0.7700 0.6600 0.6620 0.6620 126,490
Apr 11, 2023 0.9400 0.9478 0.7200 0.7221 0.7221 185,385
Apr 10, 2023 0.9750 0.9800 0.9067 0.9179 0.9179 30,979
Apr 06, 2023 0.9400 0.9500 0.9100 0.9205 0.9205 72,475
Apr 05, 2023 0.9800 0.9975 0.9300 0.9539 0.9539 312,304
Apr 04, 2023 1.8500 1.8500 0.8600 0.9700 0.9700 982,984
Apr 03, 2023 1.6800 1.8900 1.6800 1.8700 1.8700 25,574
Lannett (LCIN) : 0.149 - 35.22%
today: 149 - 0.285
52w: 0.149 – 3.72
mktcap: 1.6 million
https://www.findacode.com/ndc/labelers/Lannett_Company%2C_Inc.
Shares Outstanding 10.77M
Float 8.39M
Total Cash (mrq) 55.85M
Total Debt (mrq) 635.37M
Results of Insulin Study
The pivotal clinical trial of biosimilar insulin glargine demonstrated positive results, in line with prior expectations. The Company is co-developing this product with its strategic alliance partners within the HEC Group of companies (HEC). The single center, single-dose, double-blind, randomized, two-period, two-treatment, two-sequence, crossover study was designed to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) similarity between Lannett/HECs biosimilar insulin glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers. The study met all of its primary and secondary endpoints and no serious adverse events were reported. The data from the pivotal trial of the Company's biosimilar insulin glargine indicate that its insulin glargine is biosimilar to the reference product.
"We are pleased with the results of this crucial clinical trial of biosimilar insulin glargine," said Tim Crew, chief executive officer of Lannett. "We remain confident that biosimilar insulin glargine represents a significant commercial opportunity, and our team is diligently focused on advancing this product."
Lannett is moving forward expeditiously to complete the Biologics License Application, with the goal of submitting the application to the FDA within the next several months. Prior to filing, there are additional meaningful activities to complete, including a device differentiation study, which will run in April, and more comparability work showing HEC's insulin glargine is biosimilar to US sourced Lantus. Lannett also anticipates engaging with the FDA in a pre-submission meeting. There are significant steps necessary for the Company to receive FDA approval to effectively commercialize this product, and there is no guarantee that the Company will be successful in this regard.
The Company continues to assess the potential impacts of recent developments in the insulin market, including announcements by manufacturers related to lowering the price of insulin for patients, especially list prices, and enhancing market transparency. Lannett welcomes these initiatives to help drive greater access to this critical medicine and believes these changes dovetail with the Company's promising go-to-market approach.
Q2 Business and Financial Highlights:
• Net Sales were $80.9 Million
• Gross Margin was 18%, Adjusted Gross Margin was 19%
• Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
• $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st
Pipeline Updates:
• Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
• Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
• Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
• Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year
Apr 24, 2023 0.2300 0.2850 0.2094 0.2850 0.2850 40,646
Apr 21, 2023 0.3500 0.3500 0.2300 0.2300 0.2300 668,300
Apr 20, 2023 0.6600 0.7000 0.2500 0.3330 0.3330 1,167,800
Apr 19, 2023 0.6500 0.7196 0.6501 0.6855 0.6855 280,660
Apr 18, 2023 0.6530 0.6829 0.6530 0.6600 0.6600 30,585
Apr 17, 2023 0.7000 0.7000 0.6525 0.6525 0.6525 39,745
Apr 14, 2023 0.6400 0.7200 0.6375 0.6900 0.6900 129,657
Apr 13, 2023 0.6400 0.6960 0.6400 0.6700 0.6700 60,850
Apr 12, 2023 0.7600 0.7700 0.6600 0.6620 0.6620 126,490
Apr 11, 2023 0.9400 0.9478 0.7200 0.7221 0.7221 185,385
Apr 10, 2023 0.9750 0.9800 0.9067 0.9179 0.9179 30,979
Apr 06, 2023 0.9400 0.9500 0.9100 0.9205 0.9205 72,475
Apr 05, 2023 0.9800 0.9975 0.9300 0.9539 0.9539 312,304
Apr 04, 2023 1.8500 1.8500 0.8600 0.9700 0.9700 982,984
Apr 03, 2023 1.6800 1.8900 1.6800 1.8700 1.8700 25,574
VNET GROUP INC. (VNET) : 2.92
52w : 2.9 - 6.92
VNET Group Inc, formerly 21Vianet Group Inc, is a carrier-neutral Internet data center services provider. The Company hosts its customers' servers and networking equipment and provides interconnectivity. The Company also provides managed network services to enable customers to deliver data across the Internet through its data transmission network and smart routing technology. The Company provides value-added services, such as content delivery network services, virtual private network services and last-mile wired broadband services. It offers public cloud services, private cloud and hybrid services. The Company also offers container-based data center service. The Company's service offerings include hosting and related services, and managed network services. The Company provides hosting and related services to house servers and networking equipment in its data centers and connects them through its data transmission network, and offers other hosting related value-added services.
VNET GROUP INC. (VNET) : 2.92
52w : 2.9 - 6.92
VNET Group Inc, formerly 21Vianet Group Inc, is a carrier-neutral Internet data center services provider. The Company hosts its customers' servers and networking equipment and provides interconnectivity. The Company also provides managed network services to enable customers to deliver data across the Internet through its data transmission network and smart routing technology. The Company provides value-added services, such as content delivery network services, virtual private network services and last-mile wired broadband services. It offers public cloud services, private cloud and hybrid services. The Company also offers container-based data center service. The Company's service offerings include hosting and related services, and managed network services. The Company provides hosting and related services to house servers and networking equipment in its data centers and connects them through its data transmission network, and offers other hosting related value-added services.
U.S. ENERGY (USEG) : 1.35
52w: 1.22 - 5.28
U.S. Energy Corp. is an independent energy company. It is focused on the acquisition and development of oil and natural gas producing properties in the continental United States. Its properties and operations are in the Rockies region (Montana, Wyoming and North Dakota), the Mid-Continent (Oklahoma, Kansas and North and East Texas), West Texas, South Texas and Gulf Coast regions. It participates in oil and natural gas projects as both a non-operating working interest owner through exploration and development agreements with various oil and natural gas exploration and production companies and as an operator. It is also pursuing potential acquisitions of exploration, development and production-stage oil and natural gas properties or companies. It owns working interests in a geographically and geologically diverse portfolio of oil-weighted prospects in varying stages of exploration and development. Its oil and natural gas leases covered over 314,550 gross acres and 170,196 net acres.
Apr 01, 2023 2.1000 2.6900 1.2200 1.2700 1.2700 21,625,000
Mar 01, 2023 2.1700 2.2100 1.6600 1.7600 1.7600 1,118,000
Feb 09, 2023 0.023 Dividend
Feb 01, 2023 2.4200 2.5100 2.1600 2.1600 2.1395 708,900
Jan 01, 2023 2.3000 2.6200 2.2200 2.4300 2.4069 686,100
Dec 01, 2022 2.7300 2.7300 2.1700 2.3000 2.2781 1,400,000
Nov 07, 2022 0.023 Dividend
Nov 01, 2022 2.9500 3.0700 2.4900 2.6600 2.6140 1,529,500
Oct 01, 2022 3.0000 3.2300 2.7500 2.9800 2.9284 2,165,500
Sep 01, 2022 3.4000 3.9400 2.6700 2.9200 2.8695 3,529,400
Aug 05, 2022 0.023 Dividend
Aug 01, 2022 3.5000 4.2400 3.3000 3.4700 3.3867 4,419,700
Jul 01, 2022 3.4300 3.8400 3.2600 3.5300 3.4452 1,276,000
Jun 01, 2022 4.4100 5.2800 3.3700 3.4600 3.3769 8,493,600
May 01, 2022 3.8100 4.6500 3.6700 4.4400 4.3334 6,559,700
Apr 13, 2022 0.023 Dividend
Apr 01, 2022 4.3700 5.1900 3.7400 3.8500 3.7370 8,696,000
Mar 01, 2022 3.9800 13.9200 3.7500 4.3500 4.2223 86,797,700
U.S. ENERGY (USEG) : 1.35
52w: 1.22 - 5.28
U.S. Energy Corp. is an independent energy company. It is focused on the acquisition and development of oil and natural gas producing properties in the continental United States. Its properties and operations are in the Rockies region (Montana, Wyoming and North Dakota), the Mid-Continent (Oklahoma, Kansas and North and East Texas), West Texas, South Texas and Gulf Coast regions. It participates in oil and natural gas projects as both a non-operating working interest owner through exploration and development agreements with various oil and natural gas exploration and production companies and as an operator. It is also pursuing potential acquisitions of exploration, development and production-stage oil and natural gas properties or companies. It owns working interests in a geographically and geologically diverse portfolio of oil-weighted prospects in varying stages of exploration and development. Its oil and natural gas leases covered over 314,550 gross acres and 170,196 net acres.
Apr 01, 2023 2.1000 2.6900 1.2200 1.2700 1.2700 21,625,000
Mar 01, 2023 2.1700 2.2100 1.6600 1.7600 1.7600 1,118,000
Feb 09, 2023 0.023 Dividend
Feb 01, 2023 2.4200 2.5100 2.1600 2.1600 2.1395 708,900
Jan 01, 2023 2.3000 2.6200 2.2200 2.4300 2.4069 686,100
Dec 01, 2022 2.7300 2.7300 2.1700 2.3000 2.2781 1,400,000
Nov 07, 2022 0.023 Dividend
Nov 01, 2022 2.9500 3.0700 2.4900 2.6600 2.6140 1,529,500
Oct 01, 2022 3.0000 3.2300 2.7500 2.9800 2.9284 2,165,500
Sep 01, 2022 3.4000 3.9400 2.6700 2.9200 2.8695 3,529,400
Aug 05, 2022 0.023 Dividend
Aug 01, 2022 3.5000 4.2400 3.3000 3.4700 3.3867 4,419,700
Jul 01, 2022 3.4300 3.8400 3.2600 3.5300 3.4452 1,276,000
Jun 01, 2022 4.4100 5.2800 3.3700 3.4600 3.3769 8,493,600
May 01, 2022 3.8100 4.6500 3.6700 4.4400 4.3334 6,559,700
Apr 13, 2022 0.023 Dividend
Apr 01, 2022 4.3700 5.1900 3.7400 3.8500 3.7370 8,696,000
Mar 01, 2022 3.9800 13.9200 3.7500 4.3500 4.2223 86,797,700
TAOPING (TAOP) : 0.6503
52w: 0.55 - 1.75
Taoping Inc is a China-based company mainly providing cloud-app technologies for Smart City Internet of Things (IoT) platforms, digital advertising delivery, and other internet-based information distribution systems. The Company primarily operates through three segments. The Cloud-based Technology (CBT) segment mainly provides cloud-based products, high-end data storage servers and related services applied in private sectors including new media, healthcare, education and residential community management, and among other industries and applications. The Blockchain Technology (BT) segment is mainly engaged in cryptocurrency mining. The Traditional Information Technology (TIT) segment is mainly engaged in sales of project-based technology products and services and solutions, mainly including Geographic Information Systems (GIS), Digital Public Security Technology (DPST), and Digital Hospital Information Systems (DHIS).
TAOPING (TAOP) : 0.6503
52w: 0.55 - 1.75
Taoping Inc is a China-based company mainly providing cloud-app technologies for Smart City Internet of Things (IoT) platforms, digital advertising delivery, and other internet-based information distribution systems. The Company primarily operates through three segments. The Cloud-based Technology (CBT) segment mainly provides cloud-based products, high-end data storage servers and related services applied in private sectors including new media, healthcare, education and residential community management, and among other industries and applications. The Blockchain Technology (BT) segment is mainly engaged in cryptocurrency mining. The Traditional Information Technology (TIT) segment is mainly engaged in sales of project-based technology products and services and solutions, mainly including Geographic Information Systems (GIS), Digital Public Security Technology (DPST), and Digital Hospital Information Systems (DHIS).
RECON TECHNOLOGY (RCON) : 0.4201
52w: 0.2827 - 2.13
Shares Outstanding 40.53M
Float 27.78M
Total Cash (mrq) 269.11M
Total Cash Per Share (mrq) 7.96
Total Debt (mrq) 31.5M
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People's Republic of China. The company offers equipment, tools, and other components and parts related to oilfield production and other energy industries; and develops and sells industrial automation control and information solutions. It also provides equipment for oil and gas production and transportation, including heating furnaces and burner, as well as enhancing techniques comprising packers of fracturing; production packers; sand prevention in oil and water wells; water locating and plugging techniques; fissure shaper; fracture acidizing techniques; and electronic broken-down services to resolve block-up and freezing problems. In addition, the company offers automation systems and services, including pumping unit controller that monitors the pumping units and collects data; RTU to monitor natural gas wells and collect gas well pressure data; wireless dynamometers and wireless pressure gauges; electric multi-way valves for oilfield metering station flow control; and natural gas flow computer systems. Further, it provides Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil wells and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead and measurement station areas; and technique service for digital oilfield transformation. Additionally, the company offers oilfield waste water treatment solutions and related chemicals; oily sludge disposal solutions; and gas station operation and management solution. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
On March 2, 2023, the Company announced that it has formulated preliminary plans to expand into the plastics chemical recycling business. Recon also attended the 27th China Plastics Recycling Conference and Exhibition held on February 28 at Dongguan City of Guangdong Province to explore cutting-edge technologies that work to achieve circular economy goals in eliminating waste and pollution, keeping products and materials in continuous use, and regenerating natural systems..
On February 27, 2023, the Company announced that the mainland China variable interest entity's subsidiary, Nanjing Recon Technology Co., had achieved preliminary progress on the research and development of a new energy-efficient electric pump that is being conducted at some oilfield sites in China.
RECON TECHNOLOGY (RCON) : 0.4201
52w: 0.2827 - 2.13
Shares Outstanding 40.53M
Float 27.78M
Total Cash (mrq) 269.11M
Total Cash Per Share (mrq) 7.96
Total Debt (mrq) 31.5M
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People's Republic of China. The company offers equipment, tools, and other components and parts related to oilfield production and other energy industries; and develops and sells industrial automation control and information solutions. It also provides equipment for oil and gas production and transportation, including heating furnaces and burner, as well as enhancing techniques comprising packers of fracturing; production packers; sand prevention in oil and water wells; water locating and plugging techniques; fissure shaper; fracture acidizing techniques; and electronic broken-down services to resolve block-up and freezing problems. In addition, the company offers automation systems and services, including pumping unit controller that monitors the pumping units and collects data; RTU to monitor natural gas wells and collect gas well pressure data; wireless dynamometers and wireless pressure gauges; electric multi-way valves for oilfield metering station flow control; and natural gas flow computer systems. Further, it provides Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil wells and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead and measurement station areas; and technique service for digital oilfield transformation. Additionally, the company offers oilfield waste water treatment solutions and related chemicals; oily sludge disposal solutions; and gas station operation and management solution. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
On March 2, 2023, the Company announced that it has formulated preliminary plans to expand into the plastics chemical recycling business. Recon also attended the 27th China Plastics Recycling Conference and Exhibition held on February 28 at Dongguan City of Guangdong Province to explore cutting-edge technologies that work to achieve circular economy goals in eliminating waste and pollution, keeping products and materials in continuous use, and regenerating natural systems..
On February 27, 2023, the Company announced that the mainland China variable interest entity's subsidiary, Nanjing Recon Technology Co., had achieved preliminary progress on the research and development of a new energy-efficient electric pump that is being conducted at some oilfield sites in China.
ATERIAN (ATER) : 0,72095 -6,22%
52w : 0.672 - 5.78
Total Cash (mrq) 43.57M
Total Cash Per Share (mrq) 0.57
Total Debt (mrq) 22.75M
Shares Outstanding 81M
Float 60.06M
Aterian, Inc., together with its subsidiaries, operates as a technology-enabled consumer products company in North America and internationally. It provides Artificial Intelligence Marketplace e-Commerce Engine, a software technology platform, which uses machine learning, natural language processing, and data analytics to design, develop, market, and sell products. The company's platform offers home and kitchen appliances; kitchenware; heating, cooling, and air quality appliances, such as dehumidifiers, humidifiers, and air conditioners; health and beauty products; and essential oils under the hOmeLabs, Vremi, Squatty Potty, Xtava, RIF6, Aussie Health, Holonix, Truweo, Mueller, Pursteam, Pohl and Schmitt, Healing Solutions, Photo Paper Direct, Step and Go, and Spiralizer brands. It primarily serves individual online consumers through Amazon and other e-commerce platforms, as well as through its owned and operated websites and other marketplaces. The company was formerly known as Mohawk Group Holdings, Inc. and changed its name to Aterian, Inc. in April 2021. Aterian, Inc. was founded in 2014 and is headquartered in New York, New York.
Apr 01, 2023 0.9000 0.9500 0.7630 0.7690 0.7690 9,214,600
Mar 01, 2023 1.1700 1.2100 0.7620 0.8600 0.8600 17,820,700
Feb 01, 2023 1.5000 1.6830 1.1300 1.2000 1.2000 30,650,600
Jan 01, 2023 0.7900 1.6500 0.7100 1.5300 1.5300 80,268,800
Dec 01, 2022 1.0600 1.2000 0.6720 0.7700 0.7700 21,328,400
Nov 01, 2022 1.1100 1.2800 0.9900 1.0800 1.0800 26,208,700
Oct 01, 2022 1.2800 1.3300 0.9650 1.1000 1.1000 52,227,400
Sep 01, 2022 2.2800 2.7700 1.1910 1.2400 1.2400 46,771,500
Aug 01, 2022 2.2500 3.5800 2.2000 2.2800 2.2800 51,640,500
Jul 01, 2022 2.1300 2.7200 2.1300 2.2800 2.2800 35,127,600
Jun 01, 2022 3.2300 3.4600 2.1000 2.1600 2.1600 74,636,800
May 01, 2022 5.1700 5.7100 2.5200 3.2300 3.2300 186,045,100
Apr 01, 2022 2.4700 7.2600 2.3000 5.1300 5.1300 1,086,055,400
Mar 01, 2022 3.0000 3.0550 2.1000 2.4300 2.4300 76,630,400
Feb 01, 2022 3.2400 3.9100 2.6100 2.9900 2.9900 35,313,100
Jan 01, 2022 4.1700 4.3100 2.4500 3.2400 3.2400 68,789,700
Dec 01, 2021 4.9700 5.8000 3.7200 4.1100 4.1100 80,529,400
Nov 01, 2021 6.4000 8.3100 4.6500 4.8800 4.8800 129,029,900
Oct 01, 2021 11.2020 11.5300 6.2900 6.3900 6.3900 233,582,400
Sep 01, 2021 5.8320 19.1000 5.6400 10.8300 10.8300 1,263,945,800
Aug 01, 2021 9.2700 9.6100 3.0400 5.9600 5.9600 167,666,900
Jul 01, 2021 14.6300 15.3800 8.7800 9.0300 9.0300 14,157,200
Jun 01, 2021 18.0000 21.0700 14.3700 14.6300 14.6300 18,025,800
May 01, 2021 22.1100 22.1900 11.8100 17.9500 17.9500 24,448,700
Apr 01, 2021 31.0200 33.9700 19.6400 21.7000 21.7000 18,351,900
Mar 01, 2021 41.0100 47.8000 26.2500 29.5000 29.5000 28,614,700
Feb 01, 2021 24.0000 48.9900 22.3000 39.8800 39.8800 19,112,400
ATERIAN (ATER) : 0,72095 -6,22%
52w : 0.672 - 5.78
Total Cash (mrq) 43.57M
Total Cash Per Share (mrq) 0.57
Total Debt (mrq) 22.75M
Shares Outstanding 81M
Float 60.06M
Aterian, Inc., together with its subsidiaries, operates as a technology-enabled consumer products company in North America and internationally. It provides Artificial Intelligence Marketplace e-Commerce Engine, a software technology platform, which uses machine learning, natural language processing, and data analytics to design, develop, market, and sell products. The company's platform offers home and kitchen appliances; kitchenware; heating, cooling, and air quality appliances, such as dehumidifiers, humidifiers, and air conditioners; health and beauty products; and essential oils under the hOmeLabs, Vremi, Squatty Potty, Xtava, RIF6, Aussie Health, Holonix, Truweo, Mueller, Pursteam, Pohl and Schmitt, Healing Solutions, Photo Paper Direct, Step and Go, and Spiralizer brands. It primarily serves individual online consumers through Amazon and other e-commerce platforms, as well as through its owned and operated websites and other marketplaces. The company was formerly known as Mohawk Group Holdings, Inc. and changed its name to Aterian, Inc. in April 2021. Aterian, Inc. was founded in 2014 and is headquartered in New York, New York.
Apr 01, 2023 0.9000 0.9500 0.7630 0.7690 0.7690 9,214,600
Mar 01, 2023 1.1700 1.2100 0.7620 0.8600 0.8600 17,820,700
Feb 01, 2023 1.5000 1.6830 1.1300 1.2000 1.2000 30,650,600
Jan 01, 2023 0.7900 1.6500 0.7100 1.5300 1.5300 80,268,800
Dec 01, 2022 1.0600 1.2000 0.6720 0.7700 0.7700 21,328,400
Nov 01, 2022 1.1100 1.2800 0.9900 1.0800 1.0800 26,208,700
Oct 01, 2022 1.2800 1.3300 0.9650 1.1000 1.1000 52,227,400
Sep 01, 2022 2.2800 2.7700 1.1910 1.2400 1.2400 46,771,500
Aug 01, 2022 2.2500 3.5800 2.2000 2.2800 2.2800 51,640,500
Jul 01, 2022 2.1300 2.7200 2.1300 2.2800 2.2800 35,127,600
Jun 01, 2022 3.2300 3.4600 2.1000 2.1600 2.1600 74,636,800
May 01, 2022 5.1700 5.7100 2.5200 3.2300 3.2300 186,045,100
Apr 01, 2022 2.4700 7.2600 2.3000 5.1300 5.1300 1,086,055,400
Mar 01, 2022 3.0000 3.0550 2.1000 2.4300 2.4300 76,630,400
Feb 01, 2022 3.2400 3.9100 2.6100 2.9900 2.9900 35,313,100
Jan 01, 2022 4.1700 4.3100 2.4500 3.2400 3.2400 68,789,700
Dec 01, 2021 4.9700 5.8000 3.7200 4.1100 4.1100 80,529,400
Nov 01, 2021 6.4000 8.3100 4.6500 4.8800 4.8800 129,029,900
Oct 01, 2021 11.2020 11.5300 6.2900 6.3900 6.3900 233,582,400
Sep 01, 2021 5.8320 19.1000 5.6400 10.8300 10.8300 1,263,945,800
Aug 01, 2021 9.2700 9.6100 3.0400 5.9600 5.9600 167,666,900
Jul 01, 2021 14.6300 15.3800 8.7800 9.0300 9.0300 14,157,200
Jun 01, 2021 18.0000 21.0700 14.3700 14.6300 14.6300 18,025,800
May 01, 2021 22.1100 22.1900 11.8100 17.9500 17.9500 24,448,700
Apr 01, 2021 31.0200 33.9700 19.6400 21.7000 21.7000 18,351,900
Mar 01, 2021 41.0100 47.8000 26.2500 29.5000 29.5000 28,614,700
Feb 01, 2021 24.0000 48.9900 22.3000 39.8800 39.8800 19,112,400
CONTEXTLOGIC (WISH) : 8.015
52w: 6.86 - 63.6
Shares Outstanding 23.29M
Float 20.56M
Total Cash (mrq) 719M
Total Cash Per Share (mrq) 31.04
Total Debt (mrq) 20M
They can reduce the number of outstanding shares to 17M
SAN FRANCISCO, April 20, 2023 (GLOBE NEWSWIRE) -- ContextLogic Inc. (d/b/a Wish or the “Company”) (NASDAQ: WISH), one of the world’s largest mobile ecommerce platforms, announced today that its Board of Directors has approved a share repurchase program with authorization to repurchase up to $50 million in shares of its Class A common stock.
"We believe that the current macroeconomic environment and the strength of our balance sheet presents an attractive buying opportunity for our stock. This share repurchase program demonstrates the Board’s and management’s confidence in the future of our business and our commitment to creating long-term, sustainable value for our shareholders," said Vivian Liu, Chief Financial Officer and Chief Operating Officer of Wish. “We believe the current market does not reflect the long-term value of our shares of common stock and we believe this share repurchase program will support our efforts to unlock the long-term value and opportunity we see ahead.”
The manner, timing, and amount of any purchase will be based on an assessment of business, economic and market conditions, corporate and regulatory requirements, prevailing stock prices, and other considerations. Wish may repurchase shares of Class A common stock from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans, each in accordance with applicable securities laws and other restrictions. The repurchase program will be effective through December 31, 2023, and may be suspended, terminated, or modified at any time for any reason, and it does not obligate the Company to purchase any particular number of shares.
About Wish
Wish brings an affordable and entertaining shopping experience to millions of consumers around the world. Since our founding in San Francisco in 2010, we have become one of the largest global ecommerce platforms, connecting millions of value-conscious consumers to merchants all over the world. Wish combines technology and data science capabilities and an innovative discovery-based mobile shopping experience to create a highly-visual, entertaining, and personalized shopping experience for its users. For more information about the company or to download the Wish mobile app, visit www.wish.com or follow @Wish on Facebook, Instagram and TikTok or @WishShopping on Twitter and YouTube.
CONTEXTLOGIC (WISH) : 8.015
52w: 6.86 - 63.6
Shares Outstanding 23.29M
Float 20.56M
Total Cash (mrq) 719M
Total Cash Per Share (mrq) 31.04
Total Debt (mrq) 20M
They can reduce the number of outstanding shares to 17M
SAN FRANCISCO, April 20, 2023 (GLOBE NEWSWIRE) -- ContextLogic Inc. (d/b/a Wish or the “Company”) (NASDAQ: WISH), one of the world’s largest mobile ecommerce platforms, announced today that its Board of Directors has approved a share repurchase program with authorization to repurchase up to $50 million in shares of its Class A common stock.
"We believe that the current macroeconomic environment and the strength of our balance sheet presents an attractive buying opportunity for our stock. This share repurchase program demonstrates the Board’s and management’s confidence in the future of our business and our commitment to creating long-term, sustainable value for our shareholders," said Vivian Liu, Chief Financial Officer and Chief Operating Officer of Wish. “We believe the current market does not reflect the long-term value of our shares of common stock and we believe this share repurchase program will support our efforts to unlock the long-term value and opportunity we see ahead.”
The manner, timing, and amount of any purchase will be based on an assessment of business, economic and market conditions, corporate and regulatory requirements, prevailing stock prices, and other considerations. Wish may repurchase shares of Class A common stock from time to time through open market purchases, in privately negotiated transactions, or by other means, including through the use of trading plans, each in accordance with applicable securities laws and other restrictions. The repurchase program will be effective through December 31, 2023, and may be suspended, terminated, or modified at any time for any reason, and it does not obligate the Company to purchase any particular number of shares.
About Wish
Wish brings an affordable and entertaining shopping experience to millions of consumers around the world. Since our founding in San Francisco in 2010, we have become one of the largest global ecommerce platforms, connecting millions of value-conscious consumers to merchants all over the world. Wish combines technology and data science capabilities and an innovative discovery-based mobile shopping experience to create a highly-visual, entertaining, and personalized shopping experience for its users. For more information about the company or to download the Wish mobile app, visit www.wish.com or follow @Wish on Facebook, Instagram and TikTok or @WishShopping on Twitter and YouTube.
CRSM : 0.0024
CarSmartt, Inc.
https://smarttholdings.com/
https://www.otcmarkets.com/stock/CRSM/disclosure
Our share structure has remained the same since 2 years.
As of 08/30/2021, the number of shares outstanding of our Common Stock was:
595,304,566
04/18/2023
Outstanding Shares
595,304,566
175,117,101
11/02/2022
= less than 350.000 in the free float.
CURRENT ASSETS:
Total Current Assets 4,324
Investments 74,005
Deposit - Acquistion 1,765,707
Computer software 72,000
Loan receivable 184,453
Total Assets $ 2,100,489
no dilution so room for a big rebound
Jul 26, 2021 0.0550
https://blackbrickconstruction.com/
In June, we acquired Black Brick Construction, which specializes in ground up construction. The company has over $100K in positive cash flow and three new projects with potential for more growth.
https://smarttholdings.com/#
https://smarttholdings.com/real-estate/
https://smarttholdings.com/projects/
Smartt Inc. has purchased shares of Coinbase, netflix, fubotv, palantir and tqqq
CarSmartt entered in to an agreement with Archer Robotics, LLC., to establish a project and implementation plan to provide an autonomous vehicle platform for CarSmartt, focused on Parcels delivery with driverless cars.
Exciting things to look forward to:
– News on New Strategic Acquisitions
– News on NFTs and Cryptocurrency.
"We are excited to reveal with our Shareholders the new direction of the company, and we are ready to bring exponential shareholder value. Our commitment is to our shareholders, and we are confident that we won't let you down as we embark on this new exciting chapter."
CRSM : 0.0024
CarSmartt, Inc.
https://smarttholdings.com/
https://www.otcmarkets.com/stock/CRSM/disclosure
Our share structure has remained the same since 2 years.
As of 08/30/2021, the number of shares outstanding of our Common Stock was:
595,304,566
04/18/2023
Outstanding Shares
595,304,566
175,117,101
11/02/2022
= less than 350.000 in the free float.
CURRENT ASSETS:
Total Current Assets 4,324
Investments 74,005
Deposit - Acquistion 1,765,707
Computer software 72,000
Loan receivable 184,453
Total Assets $ 2,100,489
no dilution so room for a big rebound
Jul 26, 2021 0.0550
https://blackbrickconstruction.com/
In June, we acquired Black Brick Construction, which specializes in ground up construction. The company has over $100K in positive cash flow and three new projects with potential for more growth.
https://smarttholdings.com/#
https://smarttholdings.com/real-estate/
https://smarttholdings.com/projects/
Smartt Inc. has purchased shares of Coinbase, netflix, fubotv, palantir and tqqq
CarSmartt entered in to an agreement with Archer Robotics, LLC., to establish a project and implementation plan to provide an autonomous vehicle platform for CarSmartt, focused on Parcels delivery with driverless cars.
Exciting things to look forward to:
– News on New Strategic Acquisitions
– News on NFTs and Cryptocurrency.
"We are excited to reveal with our Shareholders the new direction of the company, and we are ready to bring exponential shareholder value. Our commitment is to our shareholders, and we are confident that we won't let you down as we embark on this new exciting chapter."
CRSM : 0.0024
52w: 0.0016 - 0.0064
https://twitter.com/matty_trader/status/1649074521364676608/photo/1
CarSmartt, Inc.
https://smarttholdings.com/
https://www.otcmarkets.com/stock/CRSM/disclosure
Our share structure has remained the same since 2 years.
As of 08/30/2021, the number of shares outstanding of our Common Stock was:
595,304,566
04/18/2023
Outstanding Shares
595,304,566
175,117,101
11/02/2022
= less than 350.000 in the free float.
CURRENT ASSETS:
Total Current Assets 4,324
Investments 74,005
Deposit - Acquistion 1,765,707
Computer software 72,000
Loan receivable 184,453
Total Assets $ 2,100,489
no dilution so room for a big rebound
Jul 26, 2021 0.0550
https://blackbrickconstruction.com/
In June, we acquired Black Brick Construction, which specializes in ground up construction. The company has over $100K in positive cash flow and three new projects with potential for more growth.
Smartt Inc. has purchased shares of Coinbase, netflix, fubotv, palantir and tqqq
CarSmartt entered in to an agreement with Archer Robotics, LLC., to establish a project and implementation plan to provide an autonomous vehicle platform for CarSmartt, focused on Parcels delivery with driverless cars.
Exciting things to look forward to:
– News on New Strategic Acquisitions
– News on NFTs and Cryptocurrency.
"We are excited to reveal with our Shareholders the new direction of the company, and we are ready to bring exponential shareholder value. Our commitment is to our shareholders, and we are confident that we won't let you down as we embark on this new exciting chapter."
CRSM : 0.0024
52w: 0.0016 - 0.0064
https://twitter.com/matty_trader/status/1649074521364676608/photo/1
CarSmartt, Inc.
https://smarttholdings.com/
https://www.otcmarkets.com/stock/CRSM/disclosure
Our share structure has remained the same since 2 years.
As of 08/30/2021, the number of shares outstanding of our Common Stock was:
595,304,566
04/18/2023
Outstanding Shares
595,304,566
175,117,101
11/02/2022
= less than 350.000 in the free float.
CURRENT ASSETS:
Total Current Assets 4,324
Investments 74,005
Deposit - Acquistion 1,765,707
Computer software 72,000
Loan receivable 184,453
Total Assets $ 2,100,489
no dilution so room for a big rebound
Jul 26, 2021 0.0550
https://blackbrickconstruction.com/
In June, we acquired Black Brick Construction, which specializes in ground up construction. The company has over $100K in positive cash flow and three new projects with potential for more growth.
Smartt Inc. has purchased shares of Coinbase, netflix, fubotv, palantir and tqqq
CarSmartt entered in to an agreement with Archer Robotics, LLC., to establish a project and implementation plan to provide an autonomous vehicle platform for CarSmartt, focused on Parcels delivery with driverless cars.
Exciting things to look forward to:
– News on New Strategic Acquisitions
– News on NFTs and Cryptocurrency.
"We are excited to reveal with our Shareholders the new direction of the company, and we are ready to bring exponential shareholder value. Our commitment is to our shareholders, and we are confident that we won't let you down as we embark on this new exciting chapter."
Lannett (LCIN) : 0.32
52w: 0.32 – 3.72
Shares Outstanding 10.77M
Float 8.39M
Q2 Business and Financial Highlights:
• Net Sales were $80.9 Million
• Gross Margin was 18%, Adjusted Gross Margin was 19%
• Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
• $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st
Pipeline Updates:
• Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
• Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
• Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
• Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year
Apr 19, 2023 0.6500 0.7196 0.6501 0.6855 0.6855 280,660
Apr 18, 2023 0.6530 0.6829 0.6530 0.6600 0.6600 30,585
Apr 17, 2023 0.7000 0.7000 0.6525 0.6525 0.6525 39,745
Apr 14, 2023 0.6400 0.7200 0.6375 0.6900 0.6900 129,657
Apr 13, 2023 0.6400 0.6960 0.6400 0.6700 0.6700 60,850
Apr 12, 2023 0.7600 0.7700 0.6600 0.6620 0.6620 126,490
Apr 11, 2023 0.9400 0.9478 0.7200 0.7221 0.7221 185,385
Apr 10, 2023 0.9750 0.9800 0.9067 0.9179 0.9179 30,979
Apr 06, 2023 0.9400 0.9500 0.9100 0.9205 0.9205 72,475
Apr 05, 2023 0.9800 0.9975 0.9300 0.9539 0.9539 312,304
Apr 04, 2023 1.8500 1.8500 0.8600 0.9700 0.9700 982,984
Apr 03, 2023 1.6800 1.8900 1.6800 1.8700 1.8700 25,574
Lannett (LCIN) : 0.32
52w: 0.32 – 3.72
Shares Outstanding 10.77M
Float 8.39M
Q2 Business and Financial Highlights:
• Net Sales were $80.9 Million
• Gross Margin was 18%, Adjusted Gross Margin was 19%
• Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters
• $19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31st
Pipeline Updates:
• Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023
• Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current Year
• Executed Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin Products Upon Approval
• Generic FLOVENT® DISKUS® ANDA Filing Anticipated by Mid Year
Apr 19, 2023 0.6500 0.7196 0.6501 0.6855 0.6855 280,660
Apr 18, 2023 0.6530 0.6829 0.6530 0.6600 0.6600 30,585
Apr 17, 2023 0.7000 0.7000 0.6525 0.6525 0.6525 39,745
Apr 14, 2023 0.6400 0.7200 0.6375 0.6900 0.6900 129,657
Apr 13, 2023 0.6400 0.6960 0.6400 0.6700 0.6700 60,850
Apr 12, 2023 0.7600 0.7700 0.6600 0.6620 0.6620 126,490
Apr 11, 2023 0.9400 0.9478 0.7200 0.7221 0.7221 185,385
Apr 10, 2023 0.9750 0.9800 0.9067 0.9179 0.9179 30,979
Apr 06, 2023 0.9400 0.9500 0.9100 0.9205 0.9205 72,475
Apr 05, 2023 0.9800 0.9975 0.9300 0.9539 0.9539 312,304
Apr 04, 2023 1.8500 1.8500 0.8600 0.9700 0.9700 982,984
Apr 03, 2023 1.6800 1.8900 1.6800 1.8700 1.8700 25,574
Recon (RCON): pre market: 0.615 + 0.1668 (+37.22%)
Pre market volume: 485.784
Shares Outstanding 40.53M
Float 27.78M
Total Cash (mrq) 269.11M
Total Cash Per Share (mrq) 7.96
Total Debt (mrq) 31.5M
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People's Republic of China. The company offers equipment, tools, and other components and parts related to oilfield production and other energy industries; and develops and sells industrial automation control and information solutions. It also provides equipment for oil and gas production and transportation, including heating furnaces and burner, as well as enhancing techniques comprising packers of fracturing; production packers; sand prevention in oil and water wells; water locating and plugging techniques; fissure shaper; fracture acidizing techniques; and electronic broken-down services to resolve block-up and freezing problems. In addition, the company offers automation systems and services, including pumping unit controller that monitors the pumping units and collects data; RTU to monitor natural gas wells and collect gas well pressure data; wireless dynamometers and wireless pressure gauges; electric multi-way valves for oilfield metering station flow control; and natural gas flow computer systems. Further, it provides Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil wells and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead and measurement station areas; and technique service for digital oilfield transformation. Additionally, the company offers oilfield waste water treatment solutions and related chemicals; oily sludge disposal solutions; and gas station operation and management solution. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
On March 2, 2023, the Company announced that it has formulated preliminary plans to expand into the plastics chemical recycling business. Recon also attended the 27th China Plastics Recycling Conference and Exhibition held on February 28 at Dongguan City of Guangdong Province to explore cutting-edge technologies that work to achieve circular economy goals in eliminating waste and pollution, keeping products and materials in continuous use, and regenerating natural systems..
On February 27, 2023, the Company announced that the mainland China variable interest entity's subsidiary, Nanjing Recon Technology Co., had achieved preliminary progress on the research and development of a new energy-efficient electric pump that is being conducted at some oilfield sites in China.
Recon (RCON): pre market: 0.615 + 0.1668 (+37.22%)
Pre market volume: 485.784
Shares Outstanding 40.53M
Float 27.78M
Total Cash (mrq) 269.11M
Total Cash Per Share (mrq) 7.96
Total Debt (mrq) 31.5M
Recon Technology, Ltd. provides hardware, software, and on-site services to companies in the petroleum mining and extraction industry in the People's Republic of China. The company offers equipment, tools, and other components and parts related to oilfield production and other energy industries; and develops and sells industrial automation control and information solutions. It also provides equipment for oil and gas production and transportation, including heating furnaces and burner, as well as enhancing techniques comprising packers of fracturing; production packers; sand prevention in oil and water wells; water locating and plugging techniques; fissure shaper; fracture acidizing techniques; and electronic broken-down services to resolve block-up and freezing problems. In addition, the company offers automation systems and services, including pumping unit controller that monitors the pumping units and collects data; RTU to monitor natural gas wells and collect gas well pressure data; wireless dynamometers and wireless pressure gauges; electric multi-way valves for oilfield metering station flow control; and natural gas flow computer systems. Further, it provides Recon SCADA oilfield monitor and data acquisition system for supervision and data collection; EPC service of pipeline SCADA system for pipeline monitoring and data acquisition; EPC service of oil and gas wells SCADA system for monitoring and data acquisition of oil wells and natural gas wells; EPC service of oilfield video surveillance and control system to control the oil and gas wellhead and measurement station areas; and technique service for digital oilfield transformation. Additionally, the company offers oilfield waste water treatment solutions and related chemicals; oily sludge disposal solutions; and gas station operation and management solution. Recon Technology, Ltd. was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China.
On March 2, 2023, the Company announced that it has formulated preliminary plans to expand into the plastics chemical recycling business. Recon also attended the 27th China Plastics Recycling Conference and Exhibition held on February 28 at Dongguan City of Guangdong Province to explore cutting-edge technologies that work to achieve circular economy goals in eliminating waste and pollution, keeping products and materials in continuous use, and regenerating natural systems..
On February 27, 2023, the Company announced that the mainland China variable interest entity's subsidiary, Nanjing Recon Technology Co., had achieved preliminary progress on the research and development of a new energy-efficient electric pump that is being conducted at some oilfield sites in China.
Time to go up back again
ReShape Lifesciences Inc. (RSLS) : 3.1000+0.4500 (+16.98%)
Apr 11, 2023 2.6500 3.8900 2.6500 3.1000 3.1000 4,178,700
Apr 10, 2023 2.6800 2.7190 2.6300 2.6500 2.6500 44,700
Apr 06, 2023 2.7400 2.8700 2.6300 2.7500 2.7500 86,600
Apr 05, 2023 2.7500 2.7500 2.6200 2.6900 2.6900 39,000
Apr 04, 2023 2.7000 2.7900 2.6000 2.6800 2.6800 37,700
Apr 03, 2023 2.6000 2.9800 2.5200 2.6100 2.6100 302,100
Mar 31, 2023 2.7100 2.8600 2.5000 2.5700 2.5700 120,900
Mar 30, 2023 2.9100 3.0650 2.7700 2.8000 2.8000 40,700
Mar 29, 2023 2.8700 2.9500 2.8000 2.9300 2.9300 98,000
Mar 28, 2023 2.9800 3.1500 2.8000 3.1200 3.1200 164,100
Mar 27, 2023 3.0400 3.1700 2.7530 2.7850 2.7850 126,000
Mar 24, 2023 3.1100 3.2900 3.0000 3.0800 3.0800 51,000
Mar 23, 2023 3.0200 3.2400 2.9800 3.1400 3.1400 82,300
Mar 22, 2023 3.0000 3.3400 2.9340 3.0200 3.0200 107,000
Mar 21, 2023 2.9500 3.0400 2.6700 3.0000 3.0000 235,500
Mar 20, 2023 3.1600 3.5600 3.0000 3.0400 3.0400 1,841,200
Mar 17, 2023 2.7700 2.8100 2.4900 2.6600 2.6600 143,900
Mar 16, 2023 2.9500 2.9500 2.6900 2.7700 2.7700 139,400
Mar 15, 2023 3.0900 3.0900 2.9000 2.9800 2.9800 93,300
Mar 14, 2023 3.1300 3.2000 3.1000 3.1000 3.1000 79,700
Mar 13, 2023 3.3200 3.3290 3.0700 3.1300 3.1300 87,500
Mar 10, 2023 3.3800 3.9100 3.2000 3.3500 3.3500 275,700
Mar 09, 2023 3.7800 3.7800 3.3500 3.3500 3.3500 107,300
Mar 08, 2023 3.8200 3.8850 3.6300 3.7000 3.7000 88,200
Mar 07, 2023 4.1000 4.1000 3.7700 3.8200 3.8200 144,900
Mar 06, 2023 4.4700 4.4700 3.9800 4.0100 4.0100 114,800
Mar 03, 2023 4.3200 4.5300 4.2900 4.4700 4.4700 96,700
Mar 02, 2023 4.2400 4.4800 4.1000 4.4200 4.4200 112,100
Mar 01, 2023 4.2500 4.2500 4.0500 4.1900 4.1900 61,800
Feb 28, 2023 4.5000 4.5100 4.1100 4.1900 4.1900 122,400
Feb 27, 2023 4.0000 4.5800 4.0000 4.5600 4.5600 276,800
Feb 24, 2023 4.1500 4.2300 3.9400 4.0300 4.0300 138,100
Feb 23, 2023 4.5700 4.6780 4.1200 4.1300 4.1300 270,500
Feb 22, 2023 4.5500 4.8000 4.3200 4.7000 4.7000 310,500
Feb 21, 2023 4.9000 5.3900 4.5200 4.5600 4.5600 610,200
Feb 17, 2023 4.3300 5.5000 4.1000 5.0000 5.0000 3,712,500
Feb 16, 2023 4.3370 4.9800 4.1900 4.3400 4.3400 609,000
Feb 15, 2023 4.0500 4.5000 3.8300 4.3700 4.3700 897,500
Feb 14, 2023 4.4400 4.4400 3.9100 4.0700 4.0700 379,100
Feb 13, 2023 4.9000 4.9000 4.2500 4.3300 4.3300 568,800
Feb 10, 2023 5.3300 5.4500 5.0000 5.0200 5.0200 525,700
Feb 09, 2023 5.8700 5.9200 5.3800 5.5300 5.5300 715,000
Feb 08, 2023 6.2000 8.2000 5.5700 5.9050 5.9050 5,910,000
Feb 07, 2023 6.6500 6.7280 6.0600 6.1600 6.1600 931,200
Feb 06, 2023 6.5000 7.4500 6.3500 6.9500 6.9500 5,427,300
Feb 03, 2023 13.1400 22.4000 11.5600 17.0400 17.0400 11,669,700
Feb 02, 2023 6.6300 6.7000 6.0600 6.3000 6.3000 708,000
Feb 01, 2023 7.1100 7.3300 6.5500 6.5600 6.5600 54,000
Jan 31, 2023 7.4100 7.5800 6.8600 7.2400 7.2400 176,500
Jan 30, 2023 8.1400 8.1400 7.5200 7.8000 7.8000 16,400
Jan 27, 2023 8.4100 8.4100 7.6500 7.8700 7.8700 32,400
Jan 26, 2023 7.6400 8.4060 7.6000 8.1700 8.1700 44,600
Jan 25, 2023 7.4100 7.7500 7.3700 7.5600 7.5600 31,400
Jan 24, 2023 7.4900 7.7500 7.4000 7.5700 7.5700 29,500
Jan 23, 2023 7.5400 7.7500 7.3900 7.6700 7.6700 27,600
Jan 20, 2023 7.1800 7.7500 7.1100 7.6800 7.6800 14,900
Jan 19, 2023 7.2200 7.4800 7.2000 7.2000 7.2000 8,900
Jan 18, 2023 8.1700 8.3200 7.2900 7.3000 7.3000 29,300
Jan 17, 2023 8.3800 8.5400 7.8200 8.0500 8.0500 40,000
Jan 13, 2023 7.8100 9.1100 7.8100 8.7200 8.7200 105,300
Jan 12, 2023 7.6100 8.2000 7.6100 7.9500 7.9500 23,300
Jan 11, 2023 7.5800 8.1800 7.5800 8.0100 8.0100 38,900
Jan 10, 2023 7.4200 8.2760 7.1800 7.8100 7.8100 115,600
Jan 09, 2023 7.5100 7.6700 7.2700 7.5600 7.5600 75,100
Jan 06, 2023 7.1500 8.1700 7.0800 7.2600 7.2600 152,000
Jan 05, 2023 9.0600 9.0600 7.2600 7.5300 7.5300 211,900
Jan 04, 2023 12.3300 13.4500 8.9000 8.9000 8.9000 886,800
Jan 03, 2023 9.6600 20.6300 9.4500 15.6600 15.6600 12,363,90
MATTHEW NACHTRAB REPORTS 27.7% STAKE IN RESHAPE LIFESCIENCES AS
NACHTRAB-PURCHASED CO'S COMMON STOCK BASED ON BELIEF THAT SUCH SECURITIES, AT CURRENT MARKET PRICES, REPRESENTED AN ATTRACTIVE INVESTMENT OPPORTUNITY
NACHTRAB - WROTE A LETTER TO THE CEO OF CO WITH RECOMMENDATIONS FOR THE MANAGEMENT TEAM’S STRATEGY GOING FORWARD
https://ir.reshapelifesciences.com/static-files/aa8a67f3-70fe-4b27-aa86-95ba8c3ce91a
I am excited for your new tenure as CEO of ReShape Lifesciences and I believe your team can rebuild and create a $100m plus market cap company with some austerity measures, leveraging assets currently owned, and capitalizing on the medicated weight loss secular trend to generate lead flow and massive revenue growth. I am willing to discuss this and advise in any way I can help.
very low free float: 442.49k
Estimated share price by March 20, 2024.
2023-03-20 2024-03-20 High 52.50 Average 39.52 Low 27.78
Time to go up back again
ReShape Lifesciences Inc. (RSLS) : 3.1000+0.4500 (+16.98%)
Apr 11, 2023 2.6500 3.8900 2.6500 3.1000 3.1000 4,178,700
Apr 10, 2023 2.6800 2.7190 2.6300 2.6500 2.6500 44,700
Apr 06, 2023 2.7400 2.8700 2.6300 2.7500 2.7500 86,600
Apr 05, 2023 2.7500 2.7500 2.6200 2.6900 2.6900 39,000
Apr 04, 2023 2.7000 2.7900 2.6000 2.6800 2.6800 37,700
Apr 03, 2023 2.6000 2.9800 2.5200 2.6100 2.6100 302,100
Mar 31, 2023 2.7100 2.8600 2.5000 2.5700 2.5700 120,900
Mar 30, 2023 2.9100 3.0650 2.7700 2.8000 2.8000 40,700
Mar 29, 2023 2.8700 2.9500 2.8000 2.9300 2.9300 98,000
Mar 28, 2023 2.9800 3.1500 2.8000 3.1200 3.1200 164,100
Mar 27, 2023 3.0400 3.1700 2.7530 2.7850 2.7850 126,000
Mar 24, 2023 3.1100 3.2900 3.0000 3.0800 3.0800 51,000
Mar 23, 2023 3.0200 3.2400 2.9800 3.1400 3.1400 82,300
Mar 22, 2023 3.0000 3.3400 2.9340 3.0200 3.0200 107,000
Mar 21, 2023 2.9500 3.0400 2.6700 3.0000 3.0000 235,500
Mar 20, 2023 3.1600 3.5600 3.0000 3.0400 3.0400 1,841,200
Mar 17, 2023 2.7700 2.8100 2.4900 2.6600 2.6600 143,900
Mar 16, 2023 2.9500 2.9500 2.6900 2.7700 2.7700 139,400
Mar 15, 2023 3.0900 3.0900 2.9000 2.9800 2.9800 93,300
Mar 14, 2023 3.1300 3.2000 3.1000 3.1000 3.1000 79,700
Mar 13, 2023 3.3200 3.3290 3.0700 3.1300 3.1300 87,500
Mar 10, 2023 3.3800 3.9100 3.2000 3.3500 3.3500 275,700
Mar 09, 2023 3.7800 3.7800 3.3500 3.3500 3.3500 107,300
Mar 08, 2023 3.8200 3.8850 3.6300 3.7000 3.7000 88,200
Mar 07, 2023 4.1000 4.1000 3.7700 3.8200 3.8200 144,900
Mar 06, 2023 4.4700 4.4700 3.9800 4.0100 4.0100 114,800
Mar 03, 2023 4.3200 4.5300 4.2900 4.4700 4.4700 96,700
Mar 02, 2023 4.2400 4.4800 4.1000 4.4200 4.4200 112,100
Mar 01, 2023 4.2500 4.2500 4.0500 4.1900 4.1900 61,800
Feb 28, 2023 4.5000 4.5100 4.1100 4.1900 4.1900 122,400
Feb 27, 2023 4.0000 4.5800 4.0000 4.5600 4.5600 276,800
Feb 24, 2023 4.1500 4.2300 3.9400 4.0300 4.0300 138,100
Feb 23, 2023 4.5700 4.6780 4.1200 4.1300 4.1300 270,500
Feb 22, 2023 4.5500 4.8000 4.3200 4.7000 4.7000 310,500
Feb 21, 2023 4.9000 5.3900 4.5200 4.5600 4.5600 610,200
Feb 17, 2023 4.3300 5.5000 4.1000 5.0000 5.0000 3,712,500
Feb 16, 2023 4.3370 4.9800 4.1900 4.3400 4.3400 609,000
Feb 15, 2023 4.0500 4.5000 3.8300 4.3700 4.3700 897,500
Feb 14, 2023 4.4400 4.4400 3.9100 4.0700 4.0700 379,100
Feb 13, 2023 4.9000 4.9000 4.2500 4.3300 4.3300 568,800
Feb 10, 2023 5.3300 5.4500 5.0000 5.0200 5.0200 525,700
Feb 09, 2023 5.8700 5.9200 5.3800 5.5300 5.5300 715,000
Feb 08, 2023 6.2000 8.2000 5.5700 5.9050 5.9050 5,910,000
Feb 07, 2023 6.6500 6.7280 6.0600 6.1600 6.1600 931,200
Feb 06, 2023 6.5000 7.4500 6.3500 6.9500 6.9500 5,427,300
Feb 03, 2023 13.1400 22.4000 11.5600 17.0400 17.0400 11,669,700
Feb 02, 2023 6.6300 6.7000 6.0600 6.3000 6.3000 708,000
Feb 01, 2023 7.1100 7.3300 6.5500 6.5600 6.5600 54,000
Jan 31, 2023 7.4100 7.5800 6.8600 7.2400 7.2400 176,500
Jan 30, 2023 8.1400 8.1400 7.5200 7.8000 7.8000 16,400
Jan 27, 2023 8.4100 8.4100 7.6500 7.8700 7.8700 32,400
Jan 26, 2023 7.6400 8.4060 7.6000 8.1700 8.1700 44,600
Jan 25, 2023 7.4100 7.7500 7.3700 7.5600 7.5600 31,400
Jan 24, 2023 7.4900 7.7500 7.4000 7.5700 7.5700 29,500
Jan 23, 2023 7.5400 7.7500 7.3900 7.6700 7.6700 27,600
Jan 20, 2023 7.1800 7.7500 7.1100 7.6800 7.6800 14,900
Jan 19, 2023 7.2200 7.4800 7.2000 7.2000 7.2000 8,900
Jan 18, 2023 8.1700 8.3200 7.2900 7.3000 7.3000 29,300
Jan 17, 2023 8.3800 8.5400 7.8200 8.0500 8.0500 40,000
Jan 13, 2023 7.8100 9.1100 7.8100 8.7200 8.7200 105,300
Jan 12, 2023 7.6100 8.2000 7.6100 7.9500 7.9500 23,300
Jan 11, 2023 7.5800 8.1800 7.5800 8.0100 8.0100 38,900
Jan 10, 2023 7.4200 8.2760 7.1800 7.8100 7.8100 115,600
Jan 09, 2023 7.5100 7.6700 7.2700 7.5600 7.5600 75,100
Jan 06, 2023 7.1500 8.1700 7.0800 7.2600 7.2600 152,000
Jan 05, 2023 9.0600 9.0600 7.2600 7.5300 7.5300 211,900
Jan 04, 2023 12.3300 13.4500 8.9000 8.9000 8.9000 886,800
Jan 03, 2023 9.6600 20.6300 9.4500 15.6600 15.6600 12,363,90
MATTHEW NACHTRAB REPORTS 27.7% STAKE IN RESHAPE LIFESCIENCES AS
NACHTRAB-PURCHASED CO'S COMMON STOCK BASED ON BELIEF THAT SUCH SECURITIES, AT CURRENT MARKET PRICES, REPRESENTED AN ATTRACTIVE INVESTMENT OPPORTUNITY
NACHTRAB - WROTE A LETTER TO THE CEO OF CO WITH RECOMMENDATIONS FOR THE MANAGEMENT TEAM’S STRATEGY GOING FORWARD
https://ir.reshapelifesciences.com/static-files/aa8a67f3-70fe-4b27-aa86-95ba8c3ce91a
I am excited for your new tenure as CEO of ReShape Lifesciences and I believe your team can rebuild and create a $100m plus market cap company with some austerity measures, leveraging assets currently owned, and capitalizing on the medicated weight loss secular trend to generate lead flow and massive revenue growth. I am willing to discuss this and advise in any way I can help.
very low free float: 442.49k
Estimated share price by March 20, 2024.
2023-03-20 2024-03-20 High 52.50 Average 39.52 Low 27.78
Wish: 0.3269-0.0886 (-21.32%)
Last 2 months:
Apr 11, 2023 0.4160 0.4300 0.3100 0.3270 0.3270 74,793,200
Apr 10, 2023 0.4000 0.4320 0.3980 0.4160 0.4160 18,978,100
Apr 06, 2023 0.3900 0.4160 0.3760 0.4100 0.4100 13,455,700
Apr 05, 2023 0.4030 0.4040 0.3810 0.3870 0.3870 14,607,000
Apr 04, 2023 0.4230 0.4290 0.3950 0.4050 0.4050 14,377,500
Apr 03, 2023 0.4380 0.4460 0.4090 0.4230 0.4230 18,779,100
Mar 31, 2023 0.3980 0.4490 0.3950 0.4460 0.4460 36,293,800
Mar 30, 2023 0.4100 0.4190 0.3910 0.3920 0.3920 17,616,800
Mar 29, 2023 0.3750 0.4050 0.3750 0.3990 0.3990 18,096,200
Mar 28, 2023 0.3730 0.3850 0.3650 0.3740 0.3740 15,095,100
Mar 27, 2023 0.3960 0.3970 0.3610 0.3770 0.3770 20,973,400
Mar 24, 2023 0.3900 0.4000 0.3830 0.3870 0.3870 17,566,200
Mar 23, 2023 0.4000 0.4230 0.3900 0.3970 0.3970 18,709,300
Mar 22, 2023 0.4100 0.4170 0.3870 0.3900 0.3900 22,647,000
Mar 21, 2023 0.4000 0.4190 0.3970 0.4100 0.4100 21,568,800
Mar 20, 2023 0.3960 0.4300 0.3810 0.3920 0.3920 29,845,000
Mar 17, 2023 0.4000 0.4100 0.3750 0.3980 0.3980 67,584,700
Mar 16, 2023 0.4050 0.4280 0.3850 0.4080 0.4080 29,986,700
Mar 15, 2023 0.4100 0.4170 0.3910 0.4020 0.4020 20,271,400
Mar 14, 2023 0.4380 0.4490 0.4120 0.4160 0.4160 25,739,500
Mar 13, 2023 0.4030 0.4390 0.3800 0.4200 0.4200 34,898,400
Mar 10, 2023 0.4300 0.4330 0.3960 0.4110 0.4110 42,152,600
Mar 09, 2023 0.4590 0.4650 0.4300 0.4300 0.4300 31,791,300
Mar 08, 2023 0.4780 0.4800 0.4510 0.4550 0.4550 29,756,000
Mar 07, 2023 0.4980 0.5000 0.4780 0.4790 0.4790 21,337,300
Mar 06, 2023 0.5130 0.5200 0.4830 0.4920 0.4920 24,015,700
Mar 03, 2023 0.4800 0.5240 0.4800 0.5040 0.5040 33,997,400
Mar 02, 2023 0.4560 0.5050 0.4500 0.4770 0.4770 38,321,700
Mar 01, 2023 0.4890 0.4940 0.4600 0.4610 0.4610 33,428,600
Feb 28, 2023 0.4900 0.5400 0.4750 0.4870 0.4870 42,315,600
Feb 27, 2023 0.5220 0.5230 0.5000 0.5010 0.5010 34,319,000
Feb 24, 2023 0.6370 0.6500 0.5000 0.5100 0.5100 78,666,900
Feb 23, 2023 0.7200 0.7350 0.6610 0.7150 0.7150 42,283,000
Feb 22, 2023 0.6800 0.7150 0.6550 0.7120 0.7120 43,203,300
Feb 21, 2023 0.7500 0.7760 0.6670 0.6670 0.6670 48,835,500
Feb 17, 2023 0.8350 0.8390 0.7120 0.7540 0.7540 56,366,900
Feb 16, 2023 0.8600 0.9690 0.8250 0.8400 0.8400 61,801,700
Feb 15, 2023 0.7500 0.9700 0.7430 0.9450 0.9450 84,528,000
Feb 14, 2023 0.9000 0.9400 0.7410 0.7500 0.7500 81,784,000
Feb 13, 2023 0.6720 1.0700 0.6200 0.8790 0.8790 175,126,700
marketcap is 1/3 of the cash.
Wish: 0.3269-0.0886 (-21.32%)
Last 2 months:
Apr 11, 2023 0.4160 0.4300 0.3100 0.3270 0.3270 74,793,200
Apr 10, 2023 0.4000 0.4320 0.3980 0.4160 0.4160 18,978,100
Apr 06, 2023 0.3900 0.4160 0.3760 0.4100 0.4100 13,455,700
Apr 05, 2023 0.4030 0.4040 0.3810 0.3870 0.3870 14,607,000
Apr 04, 2023 0.4230 0.4290 0.3950 0.4050 0.4050 14,377,500
Apr 03, 2023 0.4380 0.4460 0.4090 0.4230 0.4230 18,779,100
Mar 31, 2023 0.3980 0.4490 0.3950 0.4460 0.4460 36,293,800
Mar 30, 2023 0.4100 0.4190 0.3910 0.3920 0.3920 17,616,800
Mar 29, 2023 0.3750 0.4050 0.3750 0.3990 0.3990 18,096,200
Mar 28, 2023 0.3730 0.3850 0.3650 0.3740 0.3740 15,095,100
Mar 27, 2023 0.3960 0.3970 0.3610 0.3770 0.3770 20,973,400
Mar 24, 2023 0.3900 0.4000 0.3830 0.3870 0.3870 17,566,200
Mar 23, 2023 0.4000 0.4230 0.3900 0.3970 0.3970 18,709,300
Mar 22, 2023 0.4100 0.4170 0.3870 0.3900 0.3900 22,647,000
Mar 21, 2023 0.4000 0.4190 0.3970 0.4100 0.4100 21,568,800
Mar 20, 2023 0.3960 0.4300 0.3810 0.3920 0.3920 29,845,000
Mar 17, 2023 0.4000 0.4100 0.3750 0.3980 0.3980 67,584,700
Mar 16, 2023 0.4050 0.4280 0.3850 0.4080 0.4080 29,986,700
Mar 15, 2023 0.4100 0.4170 0.3910 0.4020 0.4020 20,271,400
Mar 14, 2023 0.4380 0.4490 0.4120 0.4160 0.4160 25,739,500
Mar 13, 2023 0.4030 0.4390 0.3800 0.4200 0.4200 34,898,400
Mar 10, 2023 0.4300 0.4330 0.3960 0.4110 0.4110 42,152,600
Mar 09, 2023 0.4590 0.4650 0.4300 0.4300 0.4300 31,791,300
Mar 08, 2023 0.4780 0.4800 0.4510 0.4550 0.4550 29,756,000
Mar 07, 2023 0.4980 0.5000 0.4780 0.4790 0.4790 21,337,300
Mar 06, 2023 0.5130 0.5200 0.4830 0.4920 0.4920 24,015,700
Mar 03, 2023 0.4800 0.5240 0.4800 0.5040 0.5040 33,997,400
Mar 02, 2023 0.4560 0.5050 0.4500 0.4770 0.4770 38,321,700
Mar 01, 2023 0.4890 0.4940 0.4600 0.4610 0.4610 33,428,600
Feb 28, 2023 0.4900 0.5400 0.4750 0.4870 0.4870 42,315,600
Feb 27, 2023 0.5220 0.5230 0.5000 0.5010 0.5010 34,319,000
Feb 24, 2023 0.6370 0.6500 0.5000 0.5100 0.5100 78,666,900
Feb 23, 2023 0.7200 0.7350 0.6610 0.7150 0.7150 42,283,000
Feb 22, 2023 0.6800 0.7150 0.6550 0.7120 0.7120 43,203,300
Feb 21, 2023 0.7500 0.7760 0.6670 0.6670 0.6670 48,835,500
Feb 17, 2023 0.8350 0.8390 0.7120 0.7540 0.7540 56,366,900
Feb 16, 2023 0.8600 0.9690 0.8250 0.8400 0.8400 61,801,700
Feb 15, 2023 0.7500 0.9700 0.7430 0.9450 0.9450 84,528,000
Feb 14, 2023 0.9000 0.9400 0.7410 0.7500 0.7500 81,784,000
Feb 13, 2023 0.6720 1.0700 0.6200 0.8790 0.8790 175,126,700
marketcap is 1/3 of the cash.
LCI: 0.7601
Shares Outstanding 10.77M
Float 8.39M
Time for recovery?? Down with low volume.
Apr 11, 2023 0.9400 0.9400 0.7601 0.7601 0.7601 146,646
Apr 10, 2023 0.9750 0.9800 0.9070 0.9180 0.9180 31,000
Apr 03, 2023 1.6800 1.8900 0.8600 0.9210 0.9210 1,393,300
Mar 27, 2023 1.5700 1.7400 1.5400 1.7400 1.7400 119,300
Mar 20, 2023 1.6500 1.8200 1.5600 1.5900 1.5900 190,800
Mar 13, 2023 1.8600 1.9500 1.6000 1.6500 1.6500 422,900
Mar 06, 2023 2.1800 2.2000 1.8500 1.9000 1.9000 171,200
Feb 27, 2023 2.1700 2.2600 2.0600 2.1400 2.1400 136,300
Feb 20, 2023 2.2400 2.4400 2.0300 2.1600 2.1600 396,000
Feb 13, 2023 2.7500 2.7990 2.4500 2.4800 2.4800 295,800
Feb 06, 2023 2.7200 3.2500 2.4040 2.7500 2.7500 567,125
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
LCI: 0.7601
Shares Outstanding 10.77M
Float 8.39M
Time for recovery?? Down with low volume.
Apr 11, 2023 0.9400 0.9400 0.7601 0.7601 0.7601 146,646
Apr 10, 2023 0.9750 0.9800 0.9070 0.9180 0.9180 31,000
Apr 03, 2023 1.6800 1.8900 0.8600 0.9210 0.9210 1,393,300
Mar 27, 2023 1.5700 1.7400 1.5400 1.7400 1.7400 119,300
Mar 20, 2023 1.6500 1.8200 1.5600 1.5900 1.5900 190,800
Mar 13, 2023 1.8600 1.9500 1.6000 1.6500 1.6500 422,900
Mar 06, 2023 2.1800 2.2000 1.8500 1.9000 1.9000 171,200
Feb 27, 2023 2.1700 2.2600 2.0600 2.1400 2.1400 136,300
Feb 20, 2023 2.2400 2.4400 2.0300 2.1600 2.1600 396,000
Feb 13, 2023 2.7500 2.7990 2.4500 2.4800 2.4800 295,800
Feb 06, 2023 2.7200 3.2500 2.4040 2.7500 2.7500 567,125
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's product portfolio includes Amphetamine IR tablets, Amphetamine ER capsules, Dicyclomine tablets, Fluphenazine tablets, Levothyroxine capsules, Methylphenidate CD capsules, Methylphenidate ER, Posaconazole DR tablets, Probenecid tablets, and Verapamil SR tablets, as well as Numbrino nasal solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, Sinotherapeutics, Respirent Pharmaceuticals Co., Ltd., HEC Pharm Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
RSLS: 3,5199 +32,83%
52w: 2.49 - 61.45
SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to its Obalon® Balloon System. The patent will cover additional claims for the Obalon® Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
“Allowance of this patent significantly strengthens our intellectual property portfolio around innovations for the Obalon Intragastric Balloon System,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “Since filing our first patent application in 2011, ReShape has pioneered the field, amassing a patent family around the intragastric balloon system, supported by a variety of novel, pending and protected inventions. Going forward, we will continue to build a defensive ‘moat’ around our product portfolio and commercialization efforts, while also taking offensive action to defend our patent position, when necessary.”
About ReShape Lifesciences™
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
RSLS: 3,5199 +32,83%
52w: 2.49 - 61.45
SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, entitled, “Systems and Methods for Determining Failure of Intragastric Devices,” related to its Obalon® Balloon System. The patent will cover additional claims for the Obalon® Balloon System and is expected to provide protection into at least January 2031, without accounting for a potential Patent Term Extension (PTE).
“Allowance of this patent significantly strengthens our intellectual property portfolio around innovations for the Obalon Intragastric Balloon System,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “Since filing our first patent application in 2011, ReShape has pioneered the field, amassing a patent family around the intragastric balloon system, supported by a variety of novel, pending and protected inventions. Going forward, we will continue to build a defensive ‘moat’ around our product portfolio and commercialization efforts, while also taking offensive action to defend our patent position, when necessary.”
About ReShape Lifesciences™
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
Wish: 0.3201
52w: 0.316 – 2.28
we see anover reaction
The 1-for-30 reverse stock split will automatically convert 30 shares of the Company’s common stock into one new share of common stock. No fractional shares will be issued in connection with the reverse stock split. Stockholders of common stock otherwise entitled to a fractional share as a result of the reverse stock split will automatically be entitled to receive an additional fraction of a share of common stock to round up to the next whole share. The reverse split will reduce the number of shares of outstanding common stock from approximately 695,000,000 shares to approximately 23,170,000 shares. Additionally, outstanding equity-based awards and other outstanding equity rights will be proportionately adjusted.
Total Cash (mrq) 719M
Total Cash Per Share (mrq) 1.03
Total Debt (mrq) 20M